ISPOR Asia Pacific 2018

The leading Asia Pacific conference for health economics and outcomes research

8 – 11 September
Keio Plaza Hotel
Tokyo, Japan

Moving Into Action: Informing Policy and Strengthening Healthcare Systems in Asia Pacific

#ISPORTokyo

NETWORK: ISPOR / WI-FI PASSWORD: TOKYO2018

www.ispor.org
HEOR is changing at a rapid pace. Let ISPOR guide you through it.

Join a global network of more than 20,000 healthcare professionals who are improving healthcare decisions

Members enjoy:
- Admission to a global network of diverse healthcare stakeholders
- Access to healthcare’s key influencers, from payers and providers to researchers and patients
- Discounts on event registrations
- Subscriptions to all ISPOR publications
- Special awards and recognition
- Exclusive online HEOR tools and cutting-edge science
- Knowledge-sharing opportunities with ISPOR colleagues

New to the field? Explore ISPOR member perks like private career development resources, members-only education and training programs, and exclusive networking opportunities!

Become a member today at www.ispor.org/membership
Dear Colleagues,

On behalf of the ISPOR Asia Consortium Executive Committee, it is my pleasure to welcome you to the ISPOR Asia Pacific 2018 Conference.

This is a truly significant event, as it represents the 15th anniversary since ISPOR's inaugural Asia Pacific Conference in Kobe, Japan in 2003. At that time, ISPOR was just beginning its presence in the Asia Pacific region, and around 250 delegates attended the Kobe Conference. Immediately following the conference, the ISPOR Asia Consortium was established with 13 founding members as the prototype of regional leadership in globalizing ISPOR, committing to furthering ISPOR’s mission in the Asia Pacific region. After 14 years of hard work and commitment by our colleagues, the ISPOR Asia Consortium has now grown to 1,000 members and the ISPOR Asia Pacific 2018 Conference is expected to be the largest ISPOR Asia Pacific Conference ever, with over 1,500 global delegates expected and over 950 presentations featured (a 38% increase in abstracts submitted from Singapore 2016).

ISPOR’s astounding growth regionally could not have happened without the support of ISPOR Asia Consortium and its membership. The Consortium, along with the ISPOR regional chapter members in Asia Pacific, have been instrumental in developing and supporting many impactful regional HEOR initiatives including publications such as *Value in Health Regional Issues*, the regional ISPOR journal recently accepted for Medline indexing, and *News Across Asia*, the quarterly newsletter of ISPOR Asia Consortium. Members also have contributed prolifically to the global body of research and developed regional HEOR conferences and trainings to build much needed capacity. ISPOR and Asia Consortium have further helped to bridge the knowledge gaps by creating effective platforms to share critical information and promote stakeholders engagement, such as the annual ISPOR HTA Roundtable in Asia Pacific and the ISPOR Patient Roundtable.

As HEOR and HTA continue to grow in importance for all healthcare stakeholders in Asia Pacific, ISPOR is deeply committed to supporting improved global healthcare decision making and outcomes. I invite you to get involved in the Society and contribute to this important mission.

I am excited to have the ISPOR Asia Pacific Conference return to Japan, particularly during this dynamic time of national debate surrounding the HTA pilot program. I am confident this Conference will provide ample opportunity for you to learn and discuss these important issues. Thank you for participating in ISPOR Asia Pacific 2018. I wish you a successful and fruitful conference—and enjoy your time in Japan.

Best regards,

Isao Kamae, MD, DrPH
2016-2018 Chair, ISPOR Asia Consortium Executive Committee, and Project Professor of Health Policy and Technology Assessment, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan
# Table of Contents

- LETTER FROM ASIA CONSORTIUM EXECUTIVE COMMITTEE CHAIR  
  3
- LETTER FROM ISPOR ASIA PACIFIC 2018 CONFERENCE PROGRAM CO-CHAIRS  
  5
- CONFERENCE PROGRAM COMMITTEE  
  6
- LETTER FROM ISPOR PRESIDENT  
  7
- CONFERENCE-AT-A-GLANCE  
  8
- CONFERENCE SUPPORTING INSTITUTIONS  
  10
- EVENT SPONSORS  
  10
- PLENARY SESSIONS  
  12
- SCHEDULE OF EVENTS
  - SATURDAY, 8 SEPTEMBER  
    14
  - SUNDAY, 9 SEPTEMBER  
    16
  - MONDAY, 10 SEPTEMBER  
    20
  - TUESDAY, 11 SEPTEMBER  
    25
- INVITATIONAL GROUP MEETINGS  
  29
- RESEARCH POSTER OVERVIEW  
  32
- EXHIBIT PROGRAM OVERVIEW  
  33
- EXHIBITOR DIRECTORY  
  33
- EXHIBIT/POSTER HALL FLOOR PLAN  
  34
- KEY INFORMATION  
  36
- CONFERENCE ROOMS FLOOR PLAN  
  38
Dear Colleagues,

We extend you a warm welcome to Tokyo for the ISPOR Asia Pacific 2018 Conference. As the leading health economics and outcomes research (HEOR) conference in Asia Pacific, ISPOR Asia Pacific 2018 will address many critical healthcare issues surrounding the pursuit of improving efficiency, quality, safety, and access to health technologies while controlling healthcare costs. ISPOR Asia Pacific 2018 has been designed for professionals who want to stay ahead of the latest trends in the field of HEOR, and it provides a unique scientific platform to facilitate interactions among stakeholders to learn the foremost in HEOR development and share best practices for its use.

With the theme “Moving into Action: Informing Policy and Strengthening Healthcare Systems in Asia Pacific,” the ISPOR Asia Pacific 2018 Conference features distinguished speakers and 3 thought-provoking plenary sessions focusing on timely and important issues facing healthcare systems across Asia Pacific. The first plenary, “Transforming Healthcare and Leveraging Digital Health for Better Health in Asia Pacific” explores the current challenges and possibilities in digital health in Asia Pacific, with valuable insight about how to grasp benefits and potential from those furthest in their digital journey. The second plenary, “Real World Evidence in Asia Pacific: Are We Ready? Is It Helpful for Decision Makers?” discusses the situation surrounding real-world evidence (RWE) and its potential value, examines readiness of RWE in healthcare decision making in the region, and explores how we should approach RWE to get the most out of it. The third plenary, “Risk Sharing Agreements: Country Experiences, Challenges, and Lessons Learned” talks about the use of risk sharing agreements to manage costs, mitigate risk, and improve patient access to innovative therapies. In addition to the plenaries, the program also includes a broad array of short courses, issue panels, workshops, and research presentations, as well as an eye-catching Welcome Reception celebrating Japanese culture and many invaluable networking opportunities with global colleagues.

We are heartened to see so many colleagues from Asia Pacific and around the world all in one place! Your strong support and active participation have made ISPOR Asia Pacific 2018 a record-breaking event. We would like to take this opportunity to thank our Program Review Committee Co-chairs, Local Review Committee members, and peer reviewers who have worked extremely hard to prepare this outstanding conference. We also wish to acknowledge the ISPOR Japan Chapter for its great support and leadership toward contributing to the Conference. Finally, we thank you the ISPOR members who support the important mission of the Society around the globe.

Enjoy ISPOR Asia Pacific 2018 and have a memorable time visiting the Tokyo metropolitan area.

Sincerely,

Takashi Fukuda, PhD
Director, Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health
Saitama, Japan

Shinya Saito, MD, PhD
Professor, Graduate School of Health Sciences
Okayama University, Okayama, Japan

Shunya Ikeda, MD, MS, DrMedSci
Vice Dean and Professor of Public Health, School of Medicine, International University of Health and Welfare
Narita, Japan

Kun Zhao, MD, PhD, MHSc
Professor & Director, Division of Health Policy Evaluation and Technology Assessment, China National Health Development Research Center
National Health Commission, Beijing, China
Conference Program Committee

ISPOR thanks the Conference Program Committee for its contributions in developing the scientific community's leading HEOR program.

CONFERENCE CO-CHAIRS:

Takashi Fukuda, PhD, Director, Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan

Shinya Saito, MD, PhD, Professor, Graduate School of Health Sciences, Okayama University, Okayama, Japan

PROGRAM COMMITTEE CO-CHAIRS:

Shunya Ikeda, MD, MS, DrMedSci, Vice Dean and Professor of Public Health, School of Medicine, International University of Health and Welfare, Narita, Japan

Kun Zhao, MD, PhD, MHSc, Professor & Director, Division of Health Policy Evaluation and Technology Assessment, China National Health Development Research Center, National Health Commission, Beijing, China

RESEARCH REVIEW COMMITTEE CO-CHAIRS:

Paul Scuffham, PhD, Professor in Health Economics, Director of the Centre for Applied Health Economics (School of Medicine), and Deputy Director of the Menzies Health Institute, Queensland, Australia

Jing Wu, PhD, Professor, Pharmaceutical Economics and Policy, Tianjin University, Tianjin, China

Eui-Kyung Lee, PhD, RPh, Professor of Pharmaceutical Policy and Outcomes Research, SungKyunKwan University, Seoul, South Korea

Christopher Carswell, MSc, Editor-in-Chief, PharmacoEconomics, Springer Nature, Auckland, New Zealand

ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS:

Vivian WY Lee, BSc, PharmD, BCPS, (Added Qualification in Cardiology), Associate Professor, School of Pharmacy, and Assistant Dean (Student Development), Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong

Bhagwan Aggarwal, PhD, MBA, MSc, MPhil, BSc, Assistant Director & Head of Department, Environmental Carcinogen Unit / Molecular Biology, National Institute of Occupational Health, Indian Council of Medical Research, Ahmedabad, India

WORKSHOP REVIEW COMMITTEE CO-CHAIRS:

Nathorn Chaiyakunapruk, PharmD, PhD, Professor of Health Economics, School of Pharmacy, Monash University Malaysia, Selangor, Malaysia

Hui-Chu Lang, PhD, Professor, Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei, Taiwan

LOCAL PROGRAM REVIEW COMMITTEE MEMBERS:

Hiroyuki Sakamaki, PhD, Professor, Department of Management, School of Management, Tokyo University of Science, Tokyo, Japan

Koijiro Shimozuma, MD, PhD, Professor, Division of Health Services Research, Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Kusatsu, Japan

Hiroyuki Okumura, PhD, Associate Director & Medical Science Staff, Medical Affairs, QA and Pharmacovigilance, Astellas Pharma Inc., Tokyo, Japan

Chisato Hamashima, MD, PhD, Section Head, Teikyo University, Tokyo, Japan

Manabu Akazawa, PhD, Professor, Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan

Shinichi Noto, MS, PhD, Professor, Niigata Sogo Gakuen School Corporation, Niigata University of Health and Welfare, Niigata, Japan

Shuichi Yamaguchi, HTA Group Manager, External Affairs Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan

Ataru Igarashi, PhD, MS, Associate Professor, Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan

Takeru Shiroiwa, PhD, Senior Researcher, Department of Health and Welfare Services, National Institute of Public Health, Saitama, Japan
Dear Colleagues,

As President of ISPOR, it is my great pleasure to welcome you to the ISPOR Asia Pacific 2018 Conference. I am very impressed to see the remarkable growth of ISPOR in Asia Pacific, with over 1,500 delegates expected at the Conference. This incredible conference in Asia Pacific is a prime example of ISPOR’s dynamic global presence and commitment to the Society’s mission of promoting health economics and outcomes research excellence to improve decision making for health globally. Apart from the international, European and regional conferences in Asia and Latin America, ISPOR also holds annual stakeholder roundtables on HTA and patient engagement around the globe, and engages members and stakeholders through its regional groups.

As a truly global organization, ISPOR has more than 20,000 international members including regional chapter members from over 120 countries. We currently have 86 regional chapters spanning the globe, and ISPOR is also represented by numerous regional groups including the Asia Consortium, Latin America Consortium, Central and Eastern Europe Consortium, Africa Network, and Arabic Network. These groups support ISPOR’s mission at the local level and do substantial work generating local research and publications, training, mentoring, network building, and promoting stakeholder engagement.

ISPOR recognizes that needs vary around the globe. With that in mind, we position ourselves accordingly to meet these needs wherever they rise. ISPOR publishes authoritative good practice reports on critical methodologies for HEOR and develops tools for researchers and decision makers. Through our special interest groups, ISPOR engages HEOR researchers to help them contribute global perspectives to topics of importance to the scientific community. And as the science of HEOR expands globally, we are committed to disseminating our good practices and building capacity through our vast network of global experts and regional chapters.

My heartfelt thanks to the Conference Committee members for their outstanding job in putting together this high-quality and interesting program. I also would like to acknowledge the ISPOR Asia Consortium leadership and ISPOR Japan Chapter for their great effort and support. Finally, I wish to recognize the ISPOR staff for their hard work in organizing yet another highly successful conference.

As a valued member and colleague in ISPOR, I thank you for your support and contributions to the Society and wish you a fruitful conference!

Best regards,

Federico Augustovski, MD, MSc, PhD
ISPOR 2018-2019 President, and Director of Health Economic Evaluations and Technology Assessment, Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina
### Saturday, 8 September 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00AM-6:00PM</td>
<td>Registration Help Desk Hours</td>
</tr>
<tr>
<td>8:00AM-12:00PM</td>
<td>Short Course Morning Session</td>
</tr>
<tr>
<td>1:00PM-5:00PM</td>
<td>Short Course Afternoon Session</td>
</tr>
<tr>
<td>5:30PM-6:30PM</td>
<td>Educational Symposium</td>
</tr>
<tr>
<td>6:45PM-7:45PM</td>
<td>Educational Symposium</td>
</tr>
<tr>
<td>8:00PM-9:00PM</td>
<td>Educational Symposium</td>
</tr>
<tr>
<td>9:00PM-10:30PM</td>
<td>Welcome Reception</td>
</tr>
</tbody>
</table>

### Sunday, 9 September 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00AM-6:00PM</td>
<td>Registration Help Desk Hours</td>
</tr>
<tr>
<td>7:00AM-12:00PM</td>
<td>Exhibitor Move In</td>
</tr>
<tr>
<td>8:00AM-12:00PM</td>
<td>Short Course Morning Session</td>
</tr>
<tr>
<td>12:00PM-6:00PM</td>
<td>Speaker Ready Room Hours</td>
</tr>
<tr>
<td>12:30PM-7:30PM</td>
<td>Research Poster Presentations – Session I</td>
</tr>
<tr>
<td>1:00PM-3:15PM</td>
<td>Welcome, Opening Speech, and First Plenary Session</td>
</tr>
<tr>
<td>3:15PM-3:45PM</td>
<td>Break, Exhibits &amp; Research Poster Presentations Viewing – Session I</td>
</tr>
<tr>
<td>3:45PM-4:45PM</td>
<td>Breakout Session</td>
</tr>
<tr>
<td>4:45PM-5:00PM</td>
<td>Break, Exhibits &amp; Research Poster Presentations Viewing – Session I</td>
</tr>
<tr>
<td>5:00PM-6:00PM</td>
<td>Breakout Session</td>
</tr>
<tr>
<td>5:00PM-6:00PM</td>
<td>ISPOR Student Career Event</td>
</tr>
<tr>
<td>6:00PM-7:30PM</td>
<td>Exhibitors’ Reception &amp; Research Poster Presentations Viewing – Session I</td>
</tr>
<tr>
<td>6:15PM-7:15PM</td>
<td>Spotlight Session</td>
</tr>
<tr>
<td>6:30PM-7:30PM</td>
<td>Poster Author Discussion Hour – Session I</td>
</tr>
<tr>
<td>7:30PM-9:00PM</td>
<td>Asia Consortium Reception</td>
</tr>
</tbody>
</table>

### Monday, 10 September 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00AM-6:00PM</td>
<td>Registration Help Desk Hours</td>
</tr>
<tr>
<td>7:15AM-8:15AM</td>
<td>Educational Symposium</td>
</tr>
<tr>
<td>8:00AM-6:00PM</td>
<td>Speaker Ready Room Hours</td>
</tr>
<tr>
<td>8:30AM-10:00AM</td>
<td>Welcome and Second Plenary Session</td>
</tr>
<tr>
<td>8:30AM-1:30PM</td>
<td>Research Poster Presentations – Session II</td>
</tr>
</tbody>
</table>
### Monday, 10 September 2018 continued

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00AM-10:30AM</td>
<td>BREAK, EXHIBITS &amp; RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II</td>
</tr>
<tr>
<td>10:30AM-11:30AM</td>
<td>BREAKOUT SESSION</td>
</tr>
<tr>
<td>11:30AM-2:30PM</td>
<td>LUNCH, EXHIBITS &amp; RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II</td>
</tr>
<tr>
<td>12:00PM-1:00PM</td>
<td>EDUCATIONAL SYMPOSIUM</td>
</tr>
<tr>
<td>12:30PM-1:30PM</td>
<td>POSTER AUTHOR DISCUSSION HOUR – SESSION II</td>
</tr>
<tr>
<td>1:15PM-2:15PM</td>
<td>EDUCATIONAL SYMPOSIUM</td>
</tr>
<tr>
<td>2:30PM-3:30PM</td>
<td>SPOTLIGHT SESSION</td>
</tr>
<tr>
<td>2:30PM-7:30PM</td>
<td>RESEARCH POSTER PRESENTATIONS – SESSION III</td>
</tr>
<tr>
<td>3:45PM-4:45PM</td>
<td>BREAKOUT SESSION</td>
</tr>
<tr>
<td>4:45PM-5:00PM</td>
<td>BREAK, EXHIBITS &amp; RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II</td>
</tr>
<tr>
<td>5:00PM-6:00PM</td>
<td>BREAKOUT SESSION</td>
</tr>
<tr>
<td>6:00PM-7:30PM</td>
<td>EXHIBITORS’ RECEPTION &amp; RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III</td>
</tr>
<tr>
<td>6:15PM-7:15PM</td>
<td>BREAKOUT SESSION</td>
</tr>
<tr>
<td>6:30PM-7:30PM</td>
<td>POSTER AUTHOR DISCUSSION HOUR – SESSION III</td>
</tr>
</tbody>
</table>

### Tuesday, 11 September 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00AM-5:00PM</td>
<td>REGISTRATION HELP DESK HOURS</td>
</tr>
<tr>
<td>7:15AM-8:15AM</td>
<td>EDUCATIONAL SYMPOSIUM</td>
</tr>
<tr>
<td>8:00AM-4:00PM</td>
<td>SPEAKER READY ROOM HOURS</td>
</tr>
<tr>
<td>8:30AM-10:15AM</td>
<td>WELCOME AND THIRD PLENARY SESSION</td>
</tr>
<tr>
<td>8:30AM-1:45PM</td>
<td>RESEARCH POSTER PRESENTATIONS – SESSION IV</td>
</tr>
<tr>
<td>10:15AM-10:45AM</td>
<td>BREAK, EXHIBITS &amp; RESEARCH POSTER PRESENTATIONS VIEWING – SESSION IV</td>
</tr>
<tr>
<td>10:45AM-11:45AM</td>
<td>BREAKOUT SESSION</td>
</tr>
<tr>
<td>11:45AM-2:45PM</td>
<td>LUNCH, EXHIBITS &amp; RESEARCH POSTER PRESENTATIONS VIEWING – SESSION IV</td>
</tr>
<tr>
<td>12:15PM-1:15PM</td>
<td>EDUCATIONAL SYMPOSIUM</td>
</tr>
<tr>
<td>12:45PM-1:45PM</td>
<td>POSTER AUTHOR DISCUSSION HOUR – SESSION IV</td>
</tr>
<tr>
<td>1:00PM-2:00PM</td>
<td>ISPOR CAREER ADVICE</td>
</tr>
<tr>
<td>1:30PM-2:30PM</td>
<td>EDUCATIONAL SYMPOSIUM</td>
</tr>
<tr>
<td>2:45PM-3:45PM</td>
<td>BREAKOUT SESSION</td>
</tr>
<tr>
<td>4:00PM-5:00PM</td>
<td>BREAKOUT SESSION</td>
</tr>
</tbody>
</table>
Conference Supporting Institutions

Asia Pacific Observatory on Health Systems and Policies
Canon Institute for Global Studies, Tokyo, Japan
Center for Socio-Economic Studies in Pharmacy, Indonesia
Centre for Applied Health Economics Griffith University, Australia
Chalapathi Institute of Pharmaceutical Sciences, India
China Center for Health Economic Research of Peking University, China
China National Health Development Research Center, National Health Commission, China
Chinese University of Hong Kong School of Pharmacy, Hong Kong
Chulalongkorn University, Thailand
Fudan University Center for Pharmacoeconomic Research and Evaluation, China
Health Policy and Technology Assessment Unit, Graduate School of Public Policy, The University of Tokyo, Japan
HTAsiaLink
Institut Sains dan Teknologi Nasional, Faculty of Pharmacy, Indonesia
Institut Teknologi Bandung, School of Pharmacy, Indonesia
Jinan University Pharmaceutical Economics and Health Technology Assessment Research Center, China
Kazakh Association of HTA, Kazakhstan
Manipal Academy of Higher Education, Manipal, India
MarksMan Healthcare Communications Pvt. Ltd., India
Monash University, Malaysia
Musashino University Institute for Global Affairs (MIGA), Tokyo, Japan
National Center for Child Health and Development, Japan
National Evidence-based Healthcare Collaborating Agency, South Korea
Philippine Health Insurance Corporation
Saw Swee Hock School of Public Health, National University of Singapore, Singapore
Shenyang Pharmaceutical University, China
Sichuan University Chinese Evidence-based Medicine Center, China
Tokyo Metropolitan Government, Tokyo Conventions & Visitors Bureau
Universitas Indonesia, Faculty of Pharmacy, Indonesia
Universitas Padjajaran, Faculty of Pharmacy, Indonesia
University of Pancasila, Faculty of Pharmacy, Indonesia

Conference Sponsors

![CBPARTNERS](image)
![HealthCore](image)
![pharmerit](image)
Your ISPOR Conference App

At your fingertips.
It's easy to personalize and maximize your ISPOR conference experience.

Search: ISPOR

NETWORK: ISPOR
WI-FI PASSWORD: TOKYO2018

ISPOR Publications
Get published. Get noticed.

ISPOR’s family of publications provide ample opportunities to contribute to the science and understanding of health economics and outcomes research (HEOR). Whether you’re conducting research for publication in peer-reviewed journals or writing about the everyday use and application of HEOR in healthcare decisions, submitting your research to ISPOR’s publications is an excellent way to get noticed and advance the field.

*Value in Health* is an international, indexed journal that publishes original research and health policy articles that help healthcare leaders make evidence-based decisions.

*Value in Health Regional Issues* is an online, MEDLINE®-indexed journal that focuses on health-related topics that impact the health systems in the following regions: 1) Asia; 2) Central and Eastern Europe, Western Asia, and Africa; and 3) Latin America.

*Value & Outcomes Spotlight* is a bimonthly HEOR news magazine that covers timely HEOR topics, updates from ISPOR leadership, and HEOR news from around the world.

505 Lawrence Square Blvd South, Lawrenceville, NJ 08648
© ISPOR – The professional society for health economics and outcomes research

www.ispor.org
Plenary Sessions Featured at ISPOR Asia Pacific 2018

FIRST PLENARY SESSION: TRANSFORMING HEALTHCARE AND LEVERAGING DIGITAL HEALTH FOR BETTER HEALTH IN ASIA PACIFIC

Digital disruption impacts every industry, and healthcare is no exception. Digital technologies are transforming the global healthcare landscape and driving healthcare towards better value by improving efficiency and quality and reducing costs. The Asia Pacific region has a highly fragmented healthcare market and its digital transformation is coming into its own. Approaches to digital health in different countries across the region differ widely. The opening plenary will explore how to fully grasp the benefits and potential of digital health: What is the current reality and future of digital health in the region? What are the drivers and barriers for the uptake and deployment of digital health? How can we take digital health to the next level?

Moderator: Erwin Loh, MBBS, LLB(Hons), MBA, MHSM, PhD, Executive Director, Innovation, Patient Safety & Experience, and Chief Medical Officer, Monash Health, Melbourne, Australia

Speakers: Polawat Witoolkollachit, MD, Director, Information Technology and Communication, Ministry of Public Health, Bangkok, Thailand; Jilan Liu, MD, MHA, Principal & Consulting Director of Greater China, Joint Commission International, and Vice President & Executive Director of Greater China, Healthcare Information and Management Systems Society, Seattle, WA, USA; Huei-Xin Lou, PharmD, MSc (Clinical Pharm), Director, Ancillary Care, Integrated Health Information Systems Pte Ltd, and Head, National Pharmacy Program Management Office, Ministry of Health, Singapore

SECOND PLENARY SESSION: REAL-WORLD EVIDENCE IN ASIA PACIFIC: ARE WE READY? IS IT HELPFUL FOR DECISION MAKERS?

Real-world evidence (RWE) is now commonly used to inform drug pricing and reimbursement decisions in Europe and North America. There also are ongoing efforts to incorporate RWE into drug development and regulatory processes in these regions. Recent years have seen an increasing interest in the use of RWE in Asia Pacific. However, the extent that RWE is embraced varies from country to country for many reasons, such as lack of data, poor data quality, data security, and privacy issues. How ready are we for RWE? Where are we now and where are we heading? In this plenary, speakers from various sectors will share their perspectives and valuable insights on the use of RWE, and address barriers impeding its use.

Moderator: Bart Barefoot, Director, VEO & Real World Evidence Policy and Advocacy, Value Evidence and Outcomes, Global Medical, GlaxoSmithKline, London, UK

Speakers: Kinwei Arnold Chan, MD, ScD, FISPE, Director, Health Data Research Center, National Taiwan University, Director, Department of Medical Research, and Director, Clinical Trial Center, National Taiwan University Hospital, Taipei, Taiwan; Xin Sun, PhD, Professor & Director, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China; Manabu Akazawa, PhD, MPH, Professor, Public Health and Epidemiology Department, Meiji Pharmaceutical University, Tokyo, Japan

THIRD PLENARY SESSION: RISK-SHARING AGREEMENTS: COUNTRY EXPERIENCES, CHALLENGES, AND LESSONS LEARNED

Interest in risk-sharing agreements (RSAs) for innovative therapies is growing due to rising cost pressures, increasing demand for value-based pricing, and uncertainty about the true effectiveness, uptake, and value of the healthcare technology. RSAs are considered as an additional approach to provide access, fairness, and mitigate financial risks to the funders and sponsors. In recent years, the number of RSAs and the number of countries using RSAs have increased significantly. Different countries use different types of RSAs under different banners, such as managed entry or managed access schemes, to solve different healthcare problems. An expert panel will share their experiences and lessons learned in RSAs, and address key issues and practical challenges in implementing these agreements.

Moderator: Jöerg Mahlich, PhD, Head, Health Economics and Outcomes Research, Janssen Pharmaceutical, and Formal Director, Health Economics in Janssen Japan KK, Neuss, Germany

Speakers: Elizabeth de Somer, Chief Executive Officer, Medicines Australia, Canberra, Australia; Jang Sae Rak, Deputy Director, Pharmaceutical Listing Division, Pharmaceutical Benefit Department, Health Insurance Review and Assessment Service, Seoul, South Korea; Gergana Zlateva, PhD, Vice President, Global Market Access-Oncology, Global Health & Value, Pfizer Inc., New York, NY, USA
ISPOR Asia Pacific 2018

8 – 11 September
Tokyo, Japan

Program & Schedule of Events

- **Saturday**  8 September
- **Sunday**  9 September
- **Monday**  10 September
- **Tuesday**  11 September

**Short Courses** are training courses offered across 7 HEOR key topic areas. The skill level ranges from introductory to advanced, and continuing education credits are available. Separate registration is required.

**Plenary Sessions** feature thought-provoking discussions on challenging topics related to healthcare policy, the application of HEOR in healthcare decision making, or methodology.

**Spotlight Sessions** highlight timely topics in HEOR and promote areas of innovation of interest to the ISPOR community.

**Issue Panels (IP)** introduce debate with multistakeholder perspectives on new or controversial issues in HEOR.

**Workshops (W)** discuss new and innovative applications in the conduct and use of HEOR or the latest on real-world data, clinical-, economic-, or patient-reported outcomes, patient-preferences, and healthcare policy.

**ISPOR Forums (F)** are presented by ISPOR Groups on country/regional health policy, scientific research/initiatives, good practices for outcomes research, research tools, or publications.

**Podium Presentations (P)** sessions consist of four 15-minute outcomes research presentations on a single topic.

**Poster Presentations Sessions** contain approximately 200 research posters per session arranged by disease, topic, or healthcare intervention with a scheduled author discussion hour.

**Symposia** are sponsored presentations related to ISPOR’s mission. The sponsor organization selects a subject of interest to delegates and arranges suitable speakers.

**Open Meetings** for ISPOR Asia Pacific 2018 are organized by the ISPOR Student Network and the ISPOR New Professional Network. These sessions will feature presentations on a wide array of topics that include career advice and scientific related content.
## Saturday 8 September

### 7:00AM-6:00PM  **REGISTRATION HELP DESK HOURS**  Hana Foyer (4th fl)

### 8:00AM-12:00PM  **SHORT COURSE MORNING SESSION**

**Introduction to Pharmacoeconomics/Health Economics  Akebono Room (47th fl)**
- **Track:** Economic Methods
- **Level:** Introductory — This course is designed for those with limited experience with pharmacoeconomics (health economics).
- **Faculty:**
  - David B. Matchar, MD, Duke-NUS Medical School, Singapore, Singapore
  - Hong Li, PhD, MPH, Digital China Health Technologies, Corp., and School of Pharmacy, Cincinnati University, Cincinnati, OH, USA

**Introduction to Real-World Data and Informatics in Healthcare  Aozora Room (47th fl)**
- **Track:** Observational Data Methods
- **Level:** Introductory — This course is designed for those with little experience with data analysis or observation.
- **Faculty:**
  - Jeff J. Guo, PhD, University of Cincinnati, Cincinnati, OH, USA
  - Kinwei Arnold Chan, MD, MPH, ScD, National Taiwan University, Taipei, Taiwan

**Elements of Pharmaceutical/Biotech Pricing I  Ensemble Room (44th fl)**
- **Track:** Use of Pharmacoeconomic / Economic / Outcomes Research Information
- **Level:** Introductory — This introductory course is designed for those with limited experience in pharmaceutical pricing and reimbursement.
- **Faculty:**
  - Jack M. Mycka, Medical Marketing Economics LLC, Montclair, NJ, USA
  - Manny Papadimitropoulos, PhD, Eli Lilly, and University of Toronto, Toronto, ON, Canada
  - Shanlian Hu, MD, MSc, Shanghai Health Development Research Center, Shanghai, China

**Introduction to Health Technology Assessment (HTA)  Harmony Room (44th fl)**
- **Track:** Use of Pharmacoeconomic / Economic / Outcomes Research Information
- **Level:** Introductory — This course is suitable for those with little or no experience with HTA.
- **Faculty:**
  - Uwe Siebert, MPH, MSc, ScD, MD, Harvard Medical School, Institute for Technology Assessment & Department of Radiology, Hall i.T., Austria
  - Yen-Huei (Tony) Tarn, PhD, MS, School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan

**NEW! Budget Impact Analysis I: A 6-Step Approach  Fuji Room (42nd fl)**
- **Track:** Economic Methods
- **Level:** Intermediate — This course is designed for those with some experience with pharmacoeconomic analysis.
- **Faculty:**
  - C. Daniel Mullins, PhD, University of Maryland, School of Pharmacy, Baltimore, MD, USA
  - Jianwei Xuan, MD, PhD, Sun Yat-sen University, Guangzhou, China

**NEW! Medical Devices in Asia Pacific: Regulatory and Reimbursement Issues  Takao Room (42nd fl)**
- **Track:** Use of Pharmacoeconomic / Economic / Outcomes Research Information
- **Level:** Intermediate — This course is designed for those with limited experience in the area of medical device reimbursement and regulatory issues and covers topics within a global context.
- **Faculty:**
  - Eugene Salole, PhD, MPH, Faculty of Medicine, UNSW, Sydney, UK
  - Jack Wong, RPh, Asia Regulatory Professional Association, Singapore

### 1:00PM-5:00PM  **SHORT COURSE AFTERNOON SESSION**

**Introduction to Modeling  Akebono Room (47th fl)**
- **Track:** Modeling Methods
- **Level:** Introductory — This course will introduce pharmacoeconomic modeling techniques such as decision analytic modeling, Markov modeling, discrete event models, and other modeling techniques and their appropriate usages with practical application, along with a review of the ISPOR Modeling Good Research Practices.
- **Faculty:**
  - Shu Chuen Li, MBA, PhD, University of Newcastle, Callaghan, NSW, Australia
  - Jipan Xie, MD, PhD, Analysis Group, Inc., New York, NY, USA

**Cost Effectiveness Analysis Alongside Clinical Trials  Aozora Room (47th fl)**
- **Track:** Economic Methods
- **Level:** Intermediate — Familiarity with economic evaluations will be helpful.
- **Faculty:**
  - Chee Jen Chang, PhD, Chang Gung University, Taoyuan, Taiwan
  - David Bin-Chia Wu, PhD, Janssen Asia Pacific, and Monash University Malaysia, Selangor, Malaysia
## Saturday 8 September

### Patient-Reported Outcomes Measures (PROMS): Cross-Cultural Development and Validation  
**Ensemble Room (44th fl)**  
**Track:** Patient-Reported Outcomes Methods  
**Level:** Introductory — This course is designed for those with limited experience with quality of life/PRO studies.  
**Faculty:** Bruce Crawford, MA, MPH, Syneos Health, Tokyo, Japan; Nan Luo, PhD, National University of Singapore, Singapore  

### Retrospective Database Design and Analysis  
**Harmony Room (44th fl)**  
**Track:** Observational Data Methods  
**Level:** Introductory — This course is designed for those with little experience with database analysis.  
**Faculty:** Jeff J. Guo, PhD, University of Cincinnati, Cincinnati, OH, USA; Xin Sun, PhD, West China Hospital of Sichuan University, Chengdu, China  

### Case Studies in Pharmaceutical / Biotech Pricing II – Advanced  
**Fuji Room (42nd fl)**  
**Track:** Use of Pharmacoeconomic / Economic / Outcomes Research Information  
**Level:** Intermediate — This course is designed for those with limited experience in the area of pharmaceutical pricing and covers topics within a global context.  
**Faculty:** Jack M. Mycka, Medical Marketing Economics LLC, Montclair, NJ, USA; Manny Papadimitropoulos, PhD, Eli Lilly, and University of Toronto, Toronto, ON, Canada; Shanlian Hu, MD, MSc, Shanghai Health Development Research Center, Shanghai, China  

### NEW! Budget Impact Analysis II: Applications and Design Issues  
**Takao Room (42nd fl)**  
**Track:** Economic Methods  
**Level:** Intermediate — This course is designed for those who have basic knowledge of budget impact analyses and desire exposure to these analyses in Excel.  
**Faculty:** Jianwei Xuan, MD, PhD, Sun Yat-sen University, Guangzhou, China; Yi Han, PhD, MS, MBA, WPP Health and Wellness/ WG Consulting, New York, NY, USA  

### 5:30PM-6:30PM  
**EDUCATIONAL SYMPOSIUM Grace Room (3rd fl)**  
**MERCK**  
Health Technology Assessment of Target Therapy on Colorectal Cancer Treatment  
*Sponsored by Merck Serono Co. Ltd.*  

### 6:45PM-7:45PM  
**EDUCATIONAL SYMPOSIUM Grace Room (3rd fl)**  
**PFIZER**  
Benefits and Limitations Underlying the Progress in the Utilization of Real-World Data in Japan  
The past decade has seen tremendous progress in the use of real-world data (RWD) by outcomes researchers for various purposes in Japan. With this, Japan-specific and non-specific limitations in the use and interpretation of RWD have become evident. In this symposium, leading experts will provide viewpoints on the benefit and limitations of RWD  
*Sponsored by Pfizer Japan Inc.*  

### 8:00PM-9:00PM  
**EDUCATIONAL SYMPOSIUM Grace Room (3rd fl)**  
**MSD**  
Use of HTA in Promoting Innovation in Healthcare in Japan, China, and Taiwan  
This symposium will provide an update on health technology assessment (HTA) and value framework development in Asia.  
*Sponsored by MSD*  

### 9:00PM-10:30PM  
**WELCOME RECEPTION Eminence Hall (5th fl)**  
The Welcome Reception provides an opportunity to network with colleagues while enjoying a drink, appetizers, and entertainment. Join us for an evening of traditional Japanese experiences. The Tokyo Convention & Visitors Bureau will provide cultural demonstrations. All attendees welcome, no separate registration required.
Sunday | 9 September

7:00AM-6:00PM | **REGISTRATION HELP DESK HOURS**  
*Hana Foyer (4th fl)*

8:00AM-12:00PM | **SHORT COURSE MORNING SESSION**

- **NEW!** **Applied Modeling**  
  *Akebono Room (47th fl)*  
  **Track:** Modeling Methods  
  **Level:** Intermediate — This course is suitable for those who are familiar with the various modeling methods.  
  **Prerequisite:** Participation in the ISPOR short course “Introduction to Modeling Methods,” or equivalent knowledge, is recommended.  
  **Faculty:**  
  Mark S. Roberts, MD, MPP, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA; David Bin-Chia Wu, PhD, Monash University Malaysia, Selangor, Malaysia

- **Statistical Methods in Health Economic Evaluations**  
  *Aozora Room (47th fl)*  
  **Track:** Use of Pharmacoeconomic / Economic / Outcomes Research Information  
  **Level:** Intermediate — This course is designed for those with a basic understanding of statistics.  
  **Faculty:**  
  Henry A. Glick, PhD, University of Pennsylvania, Philadelphia, PA; Chee Jen Chang, PhD, Chang Gung University, Taoyuan, Taiwan

- **Health-Related Quality of Life (HRQOL) Weights for Economic Evaluations**  
  *Ensemble Room (44th fl)*  
  **Track:** Patient Preference Methods  
  **Level:** Introductory — No prior knowledge of health-related quality of life is assumed.  
  **Faculty:**  
  Alex Z. Fu, PhD, Georgetown University, Washington, DC, USA; Nan Luo, PhD, National University of Singapore, Singapore

- **Network Meta-Analysis and Indirect Treatment Comparisons**  
  *Harmony Room (44th fl)*  
  **Track:** Outcomes Research Methods  
  **Level:** Intermediate — This course is designed for those with some understanding of meta-analysis.  
  **Prerequisite:** Participation in the short course “Meta-Analysis and Literature Review in Comparative Effectiveness Research,” or equivalent knowledge, is recommended.  
  **Faculty:**  
  Jeonghoon Ahn, PhD, Ewha Womans University, Seoul, South Korea; Nathorn Chaiyakunapruk, PharmD, PhD, Monash University, Petaling Jaya, Malaysia

- **Risk-Sharing/Performance-Based Schemes for Drugs and Medical Devices**  
  *Fuji Room (42nd fl)*  
  **Track:** Use of Pharmacoeconomic / Economic / Outcomes Research Information  
  **Level:** Intermediate — It will be helpful for individuals to be familiar with both the key determinants of pharmaceutical pricing and the main international health systems.  
  **Faculty:**  
  Louis P. Garrison, PhD, School of Pharmacy University of Washington, Seattle, WA, USA; Adrian Towse, MA, MPhil, Office of Health Economics, London, UK

- **NEW!** **Introduction to Big Data Analysis: Graph Analytics**  
  *Takao Room (42nd fl)*  
  **Track:** Observational Data Methods  
  **Level:** Intermediate  
  **Faculty:**  
  David R. Holmes III, PhD, Mayo Clinic College of Medicine, Rochester, MN, USA

12:30PM-7:30PM | **RESEARCH POSTER PRESENTATIONS AND EXHIBIT VIEWING - SESSION I**  
*Hana Ballroom (4th fl)*

1:00PM-1:30PM | **WELCOME**  
*Concord Ballroom (5th fl)*

Welcome from ISPOR CEO/Executive Director  
Nancy S. Berg, ISPOR, Lawrenceville, NJ, USA  
Welcome from ISPOR President  
Federico Augustovski, MD, MSc, PhD, Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina  
Conference Program Overview  
*Conference Co-Chairs:* Takashi Fukuda, PhD, National Institute of Public Health, Saitama, Japan; Shinya Saito, MD, PhD, Okayama University, Tokyo, Japan  
*Program Committee Co-Chairs:* Shunya Ikeda, MD, MS, DrMedSci, International University of Health and Welfare, Ohtawara, Japan; Kun Zhao, MD, PhD, MHSc, National Health Commission, Beijing, China  
Welcome from ISPOR Asia Consortium Executive Committee Chair  
Isao Kamae, MD, DrPH, The University of Tokyo, Tokyo, Japan

*Indicates hands-on exercises requiring the use of your personal computer.*
Sunday
9 September

1:30PM-1:45PM  OPENING SPEECH  Concord Ballroom (5th fl)
Keynote speaker: Yashuhiro Suzuki, MPH, MSc, MD, PhD, Chief Medical & Global Health Officer and Vice-Minister for Health in the Ministry of Health, Labour and Welfare (MHLW), Tokyo, Japan

1:45PM-3:15PM  FIRST PLENARY SESSION  Concord Ballroom (5th fl)
Transforming Healthcare and Leveraging Digital Health for Better Health in Asia Pacific
Moderator: Erwin Loh, MBBS, LLB (Hons), MBA, MHS, PhD, Executive Director, Innovation, Patient Safety & Experience, and Chief Medical Officer, Monash Health, Melbourne, Australia
Speakers: Gabe Rijpma, Senior Director, Health and Social Services, Microsoft Asia, Auckland, New Zealand; Polawat Witoolkollachit, MD, Director, Information Technology and Communication, Ministry of Public Health, Bangkok, Thailand; Jilan Liu, MD, MHA, Principal and Consulting Director of Greater China, Joint Commission International, and Vice President & Executive Director of Greater China, Healthcare Information and Management Systems Society, Seattle, USA; Huei-Xin Lou, PharmD, MSc (Clinical Pharma), Director, Ancillary Care, Integrated Health Information Systems Pte Ltd, and Head, National Pharmacy Program Management Office, Ministry of Health, Singapore

3:15PM-3:45PM  BREAK, EXHIBITS & RESEARCH POSTER PRESENTATION VIEWING - SESSION I  Hana Ballroom (4th fl)

3:45PM-4:45PM  BREAKOUT SESSION

Moderator: Neal Somchand, MSc, Deallus Consulting, Tokyo, Japan
Panelists: Mark Sculpher, PhD, University of York, York, UK; Takashi Fukuda, PhD, National Institute of Public Health, Wako, Japan; Christoph Glaetzer, Dipl. Kfm, Janssen, Pharmaceutical Companies of Johnson & Johnson, NJ, USA

IP2: Opportunities and Challenges in International Harmonization of HTA of Medical Devices – Gaps Between European and Asian Countries  Concord Ballroom B (5th fl)
Moderator: Rosanna Tarricone, MSc, PhD, Bocconi University, Milano, Italy
Panelists: Ataru Igarashi, PhD, The University of Tokyo, Tokyo, Japan; Sukyeong Kim, PhD, RPh, MPH, National Evidence-Based Healthcare Collaborating Agency, Seoul, Republic of South Korea

Discussion Leaders: Shunya Ikeda, MD, International University of Health and Welfare, Narita City, Japan; Nathorn Chaiyakanapruk, PharmD, PhD, Naresuan University, Phitsanulok, Thailand; Baudouin Standaert, MD, PhD, GSK Vaccines, Wavre, Belgium; Sharon Zhang, PhD, GSK Vaccines, Singapore, Singapore

Discussion Leaders: Kim Rand, PhD, University of Oslo, Oslo, Norway; Mark Oppe, PhD, EuroQol Research Foundation, Rotterdam, The Netherlands; Nan Luo, PhD, National University of Singapore, Singapore

P1: Cost Studies  Ohgi Room (4th fl)
Moderator: Gordon Liu, PhD, Peking University National School of Development and PKU China Center for Health Economic Research, Beijing, China
3:45PM-4:00PM  CS1  Factors Impacting Direct Costs of Chronic Kidney Disease Among Chinese Urban Patients in Pre-Dialysis Phase
Liu Y1, Wang J1, Yang L1, 1University of Missouri - Kansas City, Kansas City, MO, USA; 2Peking University, Beijing, China

4:00PM-4:15PM  CS2  Estimation of Life Expectancy, Expected Years of Life Lost, and Lifetime Cost Due to Intracerebral Hemorrhage in Korea
Cheon S1, Lee H1, Jang J1, Wang J1
1National Cheng Kung University, Tainan, Taiwan; 2Kyung Hee University, Seoul, Republic of South Korea

4:15PM-4:30PM  CS3  Direct Medical Costs Associated with Cardiovascular Diseases Among the HIV-Infected Patients in Taiwan: A Population-Based Study
Liao C1, Yang C2, Chen P1, Ou H2, Toh HS1, Chen Z1, Ko N2, 1Chimei Medical Center, Tainan City, Taiwan; 2National Cheng Kung University, Tainan City, Taiwan; 3Chimei Medical Center, Tainan, Taiwan

Imafuku S1, Mizukami A1, Goto Y1, Ito C1, Curran D5, Holl K1, Matsuki T1
1Fukuoka University School of Medicine, Fukuoka, Japan; 2GSK, Tokyo, Japan; 3National Cancer Center Hospital, Tokyo, Japan; 4Japan Medical Data Center Co., Ltd., Tokyo, Japan; 5GSK, Wavre, Belgium
Sunday 9 September

**P2: Cardiovascular and Diabetes Studies**  
*Grace Room (3rd fl)*

Moderator: Shan Lian Hu, MS, MD, Shanghai Health Development Research Center, Shanghai, China

3:45PM-4:00PM  
**CV1** Trends in Medication Utilization, Glycemic Control, Rates of Severe Hypoglycemia and Lower Limb Amputations Among Type 2 Diabetes Patients with Chronic Kidney Disease in Singapore from 2012 to 2017  
Tan YZ, Lim PS, Khee GY, Thumboo J, Goh S, Bee YM, Singapore General Hospital, Singapore, Singapore

4:00PM-4:15PM  
**CV2** Identification of Low-Risk Stable Cardiovascular Patients and Patient Acceptance for Fast-Track Medication Refill Service  
Lee VW¹, Kwan WH¹, Ko XC¹, Yan BP², ¹The Chinese University of Hong Kong, Shatin, Hong Kong, ²The Chinese University of Hong Kong, Hong Kong

4:15PM-4:30PM  
**CV3** The Prevalence and Burden of Hypertension and Obesity Among Patients with Type 2 Diabetes in Japan  
Carpinella CM¹, Sternbach N², Doane MJ², Fukuda T³, Chen Y⁴, Stankus AP⁵, ¹Kantar Health, San Mateo, CA, USA, ²Kantar Health, New York City, NY, USA, ³Kantar Health, Horsham, PA, USA, ⁴National Institute of Public Health, Wako, Japan, ⁵Kantar Health, Singapore, Singapore, ⁶Kantar Health, New York, NY, USA

4:30PM-4:45PM  
**CV4** Cost-Effectiveness Analysis of Acute Ischemic Stroke Treatment According to Comorbidity Index  
Han E, Yonsei University, Incheon, Republic of Korea

4:45PM-5:00PM  
**BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I**  
*Hana Ballroom (4th fl)*

5:00PM-6:00PM  
**BREAKOUT SESSION**

**IP3:** How Will Patient Centricity Be Captured in the Japanese HTA and Healthcare Reform? *Concord Ballroom A (5th fl)*

Moderator: Adrian Towse, MA, MPhil, Office of Health Economics, London, UK  
Panelists: Shunya Ikeda, MD, International University of Health and Welfare, Narita City, Japan; Makoto Kobayashi, PhD, MEng, CRECON Medical Assessment Inc., Tokyo, Japan; Durhane Wong-Rieger, PhD, MA, Canadian Organization for Rare Disorders, Toronto, ON, Canada

**IP4:** Global Alignment on Approaches to Use of Real-World Evidence in Decision Making  
*Concord Ballroom B (5th fl)*

Moderator: Rob Thwaites, MA, MCom, Takeda, London, UK  
Panelists: Nicholas Crabb, PhD, NICE, Manchester, UK; Shunichi Fukuhara, MD, PhD, Kyoto University, Kyoto, Japan; David Pearce, BPharm, MSc, Takeda Pharmaceuticals, Singapore, Singapore

**IP5:** Better the Devil You Know? QALYs and Their Alternatives in Drug Reimbursement Decision-Making  
*Concord Ballroom C (5th fl)*

Moderator: Hansoo Kim, MSc, Monash University, Melbourne, Australia  
Panelists: Mark Sculptur, PhD, University of York, York, UK; J. Jaime Caro, MDCM, McGill University, Montreal, QC, Canada; Danny Liew, PhD, MBBS, Monash University, Melbourne, Australia

**W3:** Generating and Communicating HEOR Evidence to Demonstrate Pharmaceutical Products’ Value: Recommendations for Chinese Payers on Evidence Submission Guidelines  
*Nishiki Room (4th fl)*

Discussion Leaders: Xin (Cindy) Gao, PhD, Pharmerit International, Bethesda, MD, USA; Rong Shao, PhD, China Pharmaceutical University, Nanjing, China; Shanlian Hu, MD, MSc, Shanghai Health Development Research Center, Shanghai, China

5:00PM-5:15PM  
**P3: Health Technology Assessment Studies**  
*Ohgi Room (4th fl)*

**HT1** International Comparison of HTA Decisions for Oncology Products  
Dabbous M¹, Achour L², Chaoucha L¹, Hanna E¹, Toumi M¹, ¹Aix Marseille University, Marseille, France, ²Paris Dauphine University, Paris, France, ³Market Access Society, Paris, France, ⁴Creativ-CEutical, Paris, France

**HT2** The Introduction of Health Technology Assessment in Japan: Lessons Learned from Three Other New HTA Markets (Brazil, Poland and South Korea)  
Escafit M¹, Foy CI², Paglia R³, ¹Consulting at McCann Health, London, UK; ²Consulting at McCann Health, New York, NY, USA

**HT3** An Exploration of Pharmacoeconomic Publication Trends in Japan, Singapore and China Between 2000-2018  
Wickstead RM¹, Tomlinson P¹, van Hest N¹, Steeves S², Miah F¹, Painter C¹, Uchea C¹, ¹Costello Medical, London, UK, ²Costello Medical, Cambridge, UK

**HT4** Clinical Effectiveness and Cost-Effectiveness of Sugammadex for Reversal of Neuromuscular Block: A Rapid Health Technology Assessment  
Men P¹, Gu X², Zhang H³, Zhai S¹, ¹Department of Pharmacy, Peking University Third Hospital, Beijing, China, ²MSD China Holding Co. Ltd., Shanghai, China
Sunday 9 September

**P4: Pricing Studies  Grace Room (3rd fl)**

**Moderator:** Qiang Sun, PhD, Shandong University, Shandong, China

5:00PM-5:15PM  **PR1**  Value-Based Pricing in Singapore: Is It a Race to the Bottom?  

5:15PM-5:30PM  **PR2**  The Impact of Generic Drug Entry on Market Shares and Prices of Brand-Name Drugs – Evidence from Chinese Pharmaceutical Market  
Chen J, Tian Y, Shi LW, School of Pharmaceutical Sciences, Peking University, Beijing, China

5:30PM-5:45PM  **PR3**  Drivers of High Drug Prices in Japan, a Preliminary Research  
Ueyama M1, Fukushima A2, Oku Y3, Dorey J4, Onishi Y4, François C2, Tourmi M5, 1Creativ-Ceutical K.K., Tokyo, Japan, 2Creativ-Ceutical, Paris, France, 3Kyoto University, Kyoto, Japan, 4Creativ-Ceutical, Tokyo, Japan, 5Aix-Marseille University, Marseille, France

5:45PM-6:00PM  **PR4**  A Study on Factors Influencing Drug Prices Among National Public Hospitals in the Philippines  
Apostol GL, Epimetrics, Inc., Quezon City, Philippines

5:00PM-6:00PM  **ISPOR STUDENT CAREER EVENT – HOW I GOT HERE (Open to all students)**  
Ensemble (44th fl)  
Students are invited to the first ever Student Network event at an ISPOR Asia Pacific Conference! Hear from HEOR professionals who will provide input on their career path and tips for those interested in a career in academia, government/HTA, or industry.

6:00PM-7:30PM  **EXHIBITORS’ RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I**  
Hana Ballroom (4th fl)

6:15PM-7:15PM  **SPOTLIGHT SESSION  Concord Ballroom A (5th fl)**  
Updates and Outlook on Japan's National HTA Pilot Program  
As the Japanese government currently undertakes an extensive pilot program to determine the outlook for national HTA, this session will provide an inside look on the key issues being discussed and outcomes after the program’s conclusion in April 2019.

6:30PM-7:30PM  **RESEARCH POSTER AUTHOR DISCUSSION HOUR - SESSION I**  
Hana Ballroom (4th fl)

7:30PM-9:00PM  **ASIA CONSORTIUM RECEPTION**  
Eminence Hall (5th fl)

---

### Learn. Apply. Advance.

Learn from globally renowned leaders.  
Apply knowledge to improve research methodologies.  
Advance the science: advance your career.

Don’t miss this opportunity to register for the premier educational program in health economics and outcomes research (HEOR). The ISPOR Short Course program offers engaging coursework—ranging from introductory to advanced—and hands-on learning to enhance attendees' knowledge and skills.

**Key advantages of ISPOR’s Short Course programs:**
- Learn from global leaders in the field of HEOR
- Develop your knowledge and skills through engaging coursework
- Review the latest research on best practices and best methods in HEOR
- Gain hands-on experience that translates into immediate, practical application
- Earn up to 16 CPE or CME credits (available at select conferences)

**Upcoming conference locations:** Tokyo 2018; New Orleans 2019; Bogota 2019; Copenhagen 2019

©2018 ISPOR – The professional society for health economics and outcomes research

[www.ispor.org](http://www.ispor.org)
Monday 10 September

7:00AM-6:00PM  **REGISTRATION HELP DESK HOURS**  Hana Foyer (4th fl)

7:15AM-8:15AM  **EDUCATIONAL SYMPOSIUM**  Nishiki Room (4th fl)
Challenges and Opportunities in Health Technology Assessment Development in China
Health technology assessment (HTA) has been evolving rapidly in China; however, its development has faced many challenges. In this symposium, attendees will be introduced to common methodological challenges. The presenters will discuss potential approaches for addressing the challenges, as well as opportunities for HTA development in China.
Sponsored by Analysis Group

8:30AM-10:00AM  **WELCOME & SECOND PLENARY SESSION**  Concord Ballroom (5th fl)
Welcome from ISPOR Asia Consortium Executive Committee Chair
Isao Kamae, MD, DrPH, The University of Tokyo, Tokyo, Japan
Second Plenary Session: Real-World Evidence in Asia Pacific: Are We Ready? Is It Helpful for Decision Makers?
*Moderator:* Bart Barefoot, Director, VEO and Real-World Evidence Policy and Advocacy, Value Evidence and Outcomes, Global Medical, GlaxoSmitKline, London, UK
*Sponsors:* Kinwei Arnold Chan, MD, ScD, FISPE, Director, Health Data Research Center, National Taiwan University, Director, Department of Medical Research, and Director, Clinical Trial Center, National Taiwan University Hospital, Taipei, Taiwan; Xin Sun, PhD, Professor, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China; Manabu Akazawa, PhD, MPH, Professor, Public Health and Epidemiology Department, Meiji Pharmaceutical University, Tokyo, Japan

10:00AM-10:30AM  **BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II**  Hana Ballroom (4th fl)

10:30AM-11:30AM  **BREAKOUT SESSION**
**IP6:** What Is the HTA Implication in Patient Access and What Are the Critical Factors to Make a Balance for Innovative Medicines? – 10 Years Experience with HTA in Korea  Concord Ballroom A (5th fl)
*Moderator:* Eui-Kyung Lee, PhD, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of South Korea
*Panelists:* Sungiu Kim, PhD, Novartis Korea, Seoul, Republic of South Korea; Jang Sae Rak, Deputy Director, Pharmaceutical Listing Division, Pharmaceutical Benefit Department, Health Insurance Review and Assessment Service, Seoul, South Korea; Cammy Yeun, PhD, Abbvie JAPAC, Tokyo, Japan

**IP7:** What Is the Value of Rare Disease Therapies for Developing Healthcare Systems?  Concord Ballroom B (5th fl)
*Moderator:* Ran Geng, BSE, Venture Capital, Beijing, China
*Panelists:* Gordon G Liu, PhD, National School of Development, Peking University, Beijing, China; Kevin Huang, China Organization for Rare Disorders, Beijing, China; Thomas Butt, PhD, Peking University and University College London, Beijing, China

**W4:** The New Wave in Real-World Evidence – Integrated Datasets  Concord Ballroom C (5th fl)
*Discussion Leaders:* Tom Haskell, BS, Kantar Health, Horsham, PA, USA; Ataru Igarashi, PhD, University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan; Yuji Yamamoto, MD, MBA, MinaCare Co. Ltd., Tokyo, Japan; Vince Grillo, MBA, PhD, Kantar Health, Singapore, Singapore

**W5:** Japanese HTA and Pricing: Current Methods and Future Potential  Nishiki Room (4th fl)
*Discussion Leaders:* Isao Kamae, MD, DrPH, The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan; Makoto Kobayashi, PhD, MEng, CRECON Medical Assessment Inc., Tokyo, Japan; Parashar Patel, MPA, Boston Scientific Corporation, Marlborough, MA, USA; Peter J. Neumann, ScD, Tufts Medical Center, Boston, MA, USA

10:30AM-10:45AM  **CN1** The Economic Impact of Switching to Trastuzumab Biosimilar for the Treatment of Metastatic Breast Cancer from a Chinese Payer Perspective  Ohgi Room (4th fl)
*Liu S,* Bozkaya D, Brown D, Xcenda, LLC, Palm Harbor, FL, USA

10:45AM-11:00AM  **CN2** Cross-Country Comparison of Cancer-Specific Multi-Attribute Utility Instruments: Relative Weighting and Ranking of Health-Related Quality of Life Domains in Country-Specific Utility Algorithms  Ohgi Room (4th fl)
*King MT,* Norman R, Kemmler G, McTaggart-Cowan H, Rowen D, Pickard AS, Viney R, 1University of Sydney, Sydney,
Monday 10 September

Australia, 1Curtin University, Perth, Australia, 2Medical University of Innsbruck, Innsbruck, Austria, 3Canadian Centre for Applied Research in Cancer Control, Vancouver, BC, Canada, 4University of Sheffield, Sheffield, UK, 4University of Illinois at Chicago, Chicago, IL, USA, 5University of Technology, Sydney, Sydney, Australia

11:00AM-11:15AM  **CN3** Cost Effectiveness Analysis of Using a Novel Diagnostic Test in Gastric Cancer Screening Programs for Population at Intermediate and High Risk
Kapoor R1, Feng Z1, So J1, Zou R1, Zhou L1, Too H1, Yeoh KG1, Yi Kong T1, Yong JS1, 1National University of Singapore, Singapore, 2National University of Singapore, Singapore, 3National University Hospital, Singapore, Singapore, 4Mirxes, Singapore, Singapore

11:15AM-11:30AM  **CN4** Economic Burden of Lung Cancer Attributable to Smoking in China in 2015
Shi J1, Liu C1, Ren J1, Huang H1, Wang L1, Parascandola M1, Wu N1, Zou X1, Liu G1, He J1, Dai M1, 1Program Office for Cancer Screening in Urban China, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2Office of Cancer Early Diagnosis and Early Treatment, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 3National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 4National Cancer Institute, Bethesda, MD, USA, 5National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 6National Office for Cancer Prevention and Control, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 7School of Health Management, Harbin Medical University, Heilongjiang, China

**P6:** Medical Device and Diagnostics Studies  **Grace Room (3rd fl)**
Moderator: Kenneth K. C. Lee, MPhil, PhD, Monash University Malaysia, Selangor, Malaysia

10:30AM-10:45AM  **MD1** Sudden Cardiac Death After Revascularization in Patients with Coronary Artery Disease and Left Ventricular Dysfunction
Wang S1, Borah BJ1, Dunlay SM1, Chamberlain A2, Liu J1, 1Beijing Anzhen Hospital, Beijing, China, 2Mayo Clinic College of Medicine, Rochester, MN, USA

10:45AM-11:00AM  **MD2** Economic Analysis of Urea-Excipient Drug-Coated Balloon Therapy for Treatment of Femoropopliteal Artery Disease in Japan
Pietzsch JB1, Garner AM1, Hosotani M2, Manda B1, Geisler BP1, Yoko H4, ‘Wing Tech Inc., Menlo Park, CA, USA, 1Medtronic Japan, Tokyo, Japan, 2Medtronic Cardiovascular, Santa Rosa, CA, USA, 3Fukuoka Sanno Hospital, Fukuoka, Japan

11:00AM-11:15AM  **MD3** Cost-Effectiveness Analysis of Mechanical Thrombectomy with ReVive SE® vs Intravenous Thrombolysis for the Treatment of Acute Ischemic Stroke in China
Jia Y1, Liu J2, Yang P1, Zhang Y1, Zhang Y2, Li Z3, Zhang L3, Lin Z1, Tan J2, Xuan J2, 1Johnson & Johnson Medical (China) Ltd., Shanghai, China, 2Changhai Hospital, Shanghai, China, 3Shanghai Centennial Scientific Co. Ltd., Shanghai, China, 4Health Economic Research Institute, School of Pharmacy, Sun Yat-Sen University, Guangzhou, China

11:15AM-11:30AM  **MD4** Validation of the Malay Version of Mini-Addenbrooke's Cognitive Examination: A Pilot Study
Hammad MA1, Syed Sulaiman SA1, Aziz NA2, Shabab A2, Saeed M1, Mohamed Noor DA3, 1Universiti Sains Malaysia, Penang, Malaysia, 2Penang General Hospital, Penang, Malaysia

11:30AM-2:30PM  **LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II**  **Hana Ballroom (4th fl)**

12:00PM-1:00PM  **EDUCATIONAL SYMPOSIUM**  **Nishiki Room (4th fl)**
Appraisal and Assessment with an Emphasis on Patient Advocacy
The objective of this symposium is to share the experience and importance of different health technology assessment (HTA) bodies with patient advocates on the committee, their role, and how it has made a positive impact on the decision making of these bodies.  
**Sponsored by Eli Lilly & Company**

12:30PM-1:30PM  **RESEARCH POSTER AUTHOR DISCUSSION HOUR - SESSION II**  **Hana Ballroom (4th fl)**

1:15PM-2:15PM  **EDUCATIONAL SYMPOSIUM**  **Nishiki Room (4th fl)**
Evaluations on the Health Technology Assessment Era in Japan – From Governmental, Academic, and Pharmaceutical Perspectives
Using cost-effectiveness analysis as a key evaluation, a health technology assessment system has been piloted in Japan during the past few years and will be fully implemented soon. Invited speakers from the advisory committee to the Japanese government, academia, and the pharmaceutical industry will share views on the experience and outlook of HTA in Japan.  
**Sponsored by Otsuka Pharmaceutical Co., Ltd.**

www.ispor.org  21
Monday 10 September

2:30PM-3:30PM  SPOTLIGHT SESSION

IP8: Global Horizon Scanning: Policy Implications and Practicalities  Concord Ballroom A (5th fl)
Introducer: Isao Kamae, MD, DrPH, Professor of Health Technology Assessment and Public Policy, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan
Moderator: Karen Facey, Senior Research Fellow, University of Edinburgh, Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK
Panelists: Suky Ae Kim, MD, PhD, Director, Coordinating Center for National Health Clinical Research in National Evidence-Based Healthcare Collaborating Agency (NECA), Seoul, South Korea; Franz Pichler, PhD, Senior Director, Global Public Policy, Eli Lilly, Sydney, Australia; Kun Zhao, MD, PhD, MHSc, Professor & Director, Division of Health Policy Evaluation and Technology Assessment, China National Health Development Research Center, National Health Commission, Beijing, China

W6: Response-Based Cost-Effectiveness Modeling in Immuno-Oncology  Concord Ballroom B (5th fl)
Discussion Leaders: J. Jaime Caro, MDCM, McGill University, Montreal, QC, Canada; Noemi Muszbek, MSc, Evidera, London, UK; Joe Zhuo, PhD, Merck KGaA, Billerica, MA, USA

W7: How Can HTA Methods Be Adapted to Meet the Special Characteristics of Medical Devices?  Concord Ballroom C (5th fl)
Discussion Leaders: Rosanna Tarricone, MSc, PhD, Bocconi University, Milano, Italy; Michael F. Drummond, MCom, DPhil, University of York, York, UK; Rei Goto, MD, PhD, Keio University, Yokohama, Japan

2:30PM-7:30PM  RESEARCH POSTER PRESENTATIONS - SESSION III  Hana Ballroom (4th fl)

3:45PM-4:45PM  BREAKOUT SESSION

IP9: A Real-World Data (RWD) Roadmap in China: Challenges and Opportunities for In Vitro Diagnostics  Concord Ballroom A (5th fl)
Moderator: Meng Chun Gong, MD, National Rare Diseases Registry System of China, Beijing, China
Panelists: Si Yan Zhan, PhD, Peking University, Beijing, China; Yan Xiao, MD, PhD, Roche Diagnostics, Pleasanton, CA, USA; Xiao Qing Liu, MD, Peking Union Medical College Hospital, Beijing, China

IP10: What Evidence Should Be Used to Quantify Cost-Effectiveness Thresholds for Decision-Making in the Asia Pacific Region?  Concord Ballroom B (5th fl)
Moderator: Ryota Nakamura, PhD, Hitotsubashi University, Tokyo, Japan
Panelists: Mark Sculpher, PhD, University of York, York, UK; Yot Teerawattananon, PhD, Health Intervention and Technology Assessment Program, Muang, Nonthaburi, Thailand; Jonathan Karnon, PhD, The University of Adelaide, Adelaide, Australia

W8: From Data Science to Decision Science in Health Technology Assessment: A Case of Oncology  Concord Ballroom C (5th fl)
Discussion Leaders: Jittrakul Leartsakulanitch, PhD, Janssen Asia Pacific, Singapore; Bruce Crawford, MPH, MA, Syneos Health, Tokyo, Japan; Eui-Kyung Lee, PhD, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of South Korea; Kenshi Suzuki, MD, PhD, Department of Myeloma Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan

W9: Bridging the Gap Between Efficacy and Effectiveness: Using Both Real-world and Trial-based Evidence to Improve Clinical Decision Making  Nishiki Room (4th fl)
Discussion Leaders: Fei-Yuan Sharon Hsiao, Associate Professor, National Taiwan University; Bor-Sheng Ko, Attending Physician and Clinical Assistant Professor, National Taiwan University Hospital; Ming-Hui Tai, Amgen, Han-I Wang, Research fellow, University of York

W10: Treatment Patterns Using Administrative Claims Data: Guiding Principles for Imperfect Data  Ohgi Room (4th fl)
Discussion Leaders: Steve Sherman, MPH, Creativ- Ceutical, Chicago, IL, USA; Kenji Adachi, PhD, Eli Lilly, Japan; Yoshiie Onishi, DrPH, MS, MPH, RPh, Creativ- Ceutical K.K., Tokyo, Japan; Samuel Aballea, PhD, Creativ- Ceutical, Paris, France

P7: Infectious Disease Studies  Grace Room (3rd fl)
Moderator: Paul Scuffham, PhD, Griffith University and Menzies Health Institute, Queensland, Australia

IN1: Impact of Sofosbuvir-Based Regimens for Chronic Hepatitis C Infection: A Work Productivity Model from Mainland China
Ye Xi, Xu X, Xie Q, Tang H, Xuan, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Department of Infectious Diseases, Peking University First Hospital, Beijing, China; Shanghai Jiaotong University School of Medicine, Shanghai, China; West China Hospital of Sichuan, Chengdu, China; Health Economic Research Institute, School of Pharmacy, Sun Yat-Sen University, Guangzhou, China
Monday 10 September

4:00PM-4:15PM  IN2  Trends of Prescription Pattern in Pediatric Intensive Care Unit: An Observational Study  Magaji BS1, Ashwin B1, Saraswathy GR1, Krishna Murthy M1, Ramya R1, 1M S Ramaiah University of Applied Sciences, Bangalore, India, 2Ramaiah University of Applied Sciences, Bangalore, India

4:15PM-4:30PM  IN3  How Much Do Malaysians Value Dengue Vaccine? Evaluating the Willingness to Pay for Hypothetical Dengue Vaccine with Two-Part Model  Yeo HY1, Shafie AA1, 1Clinical Research Center, Hospital Seberang Jaya, Seberang Jaya, Penang, Malaysia, 2Universiti Sains Malaysia, Penang, Malaysia

4:30PM-4:45PM  IN4  The Public Health Impact and Cost-Effectiveness of School-Based Nine-Valent Human Papillomavirus Female Vaccination Compared with Bi-Valent and Quadrivalent Vaccination in Malaysia  Woo Y1, Hsu T1, Pavelyev A1, Le Van R1, Prabhu VS1, 1University of Malaya, Kuala Lumpur, Malaysia, 2MSD Pharma (Singapore) Pte. Ltd, Singapore, Singapore, 3Merck & Co., Inc., Kenilworth, NJ, USA

4:45PM-5:00PM  BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II  Hana Ballroom (4th fl)

5:00PM-6:00PM  BREAKOUT SESSION

IP11: A Trial HTA Introduction in Japan: Learning and Way Forward  Concord Ballroom A (5th fl)
Moderator: Wonjoo Jung, MPharm, Janssen, Tokyo, Japan
Panelists: Takashi Fukuda, PhD, National Institute of Public Health, Wako, Japan; Ataru Igarashi, PhD, The University of Tokyo, Tokyo, Japan; Christopher Hourigan, MBA, PhRMA, Tokyo, Japan

IP12: How to Measure and Value Health Benefits to Facilitate Priority Setting for Pediatric Population: Development and Application Issues  Concord Ballroom B (5th fl)
Moderator: Gang Chen, PhD, MSc, Monash University, Melbourne, Australia
Panelists: Nan Luo, PhD, National University of Singapore, Singapore; Ruoyan Gai, PhD, National Center for Child Health and Development of Japan, Tokyo, Japan

W11: Value of Innovative Medications from the Patients’ Perspective in Asia  Concord Ballroom C (5th fl)
Discussion Leaders: Gordon G Liu, PhD, National School of Development; Peking University, Beijing, China; Hae Sun Suh, PhD, MPharm, MA, Pusan National University, Busan, Republic of South Korea; Jasmine Pwu, PhD, MOHW, Taipei, Taiwan; Rei Goto, MD, PhD, Keio University, Yokohama, Japan

W12: Dragon’s Offer: Risk Sharing for Early Access to Innovation in China  Nishiki Room (4th fl)
Discussion Leaders: Sandeep Duttagupta, PhD, CBPartners, New York, NY, USA; Jinfeng Ding, MSc, Taikang Group Online Health Service, Beijing, China; Qiao Gong, BSc, Taikang Group Online Health Service, Beijing, China; Jun Li, PhD, RDPAC, Beijing, China

P8: Medication Adherence Studies  Ohgi Room (4th fl)
Moderator: Ming Hu, PhD, West China School of Pharmacy, Sichuan University, Chengdu, China

5:00PM-5:15PM  AD1  Adherence to Insulin in Singaporean Pediatric Type 1 Diabetes Patients and Its Association with Glycemic Control and Healthcare Utilization  Chua B1, Lim XY1, Poh KM1, Stephanie J1, Cheen M1, Lim ST1, Lek N1, 1KK Women’s and Children’s Hospital, Singapore, Singapore; 2Singapore General Hospital, Singapore, Singapore

5:15PM-5:30PM  AD2  Assessment of Patient Compliance, Its Associated Factors and Predictive Internlations  Butt H1, Muzaffar Z2, Rasool P1, Mohsin M1, 1Islamia University Bahawalpur, Multan, Pakistan, 2Bahauddin Zakriya University, Multan, Pakistan

5:30PM-5:45PM  AD3  Comparison of Persistence and Adherence Between Fixed-Dose Combination Therapy and Two-Pill Combination Therapy in Japanese Patients with Type 2 Diabetes Mellitus Using Two Administrative Databases  Oh A1, Katou H1, Kisanuki K1, Onishi Y1, Guelfiucci P1, Amri H1, Argoubi R1, Shimasaki Y1, Nishimura R1, 1Takeda Pharmaceutical Company Ltd., Tokyo, Japan; 2Creativ-Cellu, Tokyo, Japan; 3Creativ-Cellu, Tokyo, Japan; 4Creativ-Cellu, Paris, France; 5Creativ-Cellu, Tunis, Tunisia; 6Ikei University School of Medicine, Tokyo, Japan

5:45PM-6:00PM  AD4  Incorporating Adherence in Cost-Effectiveness Analyses of Interventions for Asthma Treatment: A Systematic Review  Chongmelaxme B1, Chaiyakunapruk N2, Dilokthornsakul P1, 1Naresuan University, Phitsanulok, Thailand, 2Monash University, Petaling Jaya, Malaysia

P9: Modeling Methods  Grace Room (3rd fl)
Moderator: Chee Jen (CJ) Chang, PhD, Chang Gung University, Taoyuan, Taiwan

5:00PM-5:15PM  MO1  Extrapolation of Individual Survival Curves: What Can We Learn from Registry Data?  Gray I1, Sullivan T1, Sorich M1, Sailer A1, Karnon J1, 1The University of Adelaide, Adelaide, Australia, 2Flinders University, Bedford Park, Australia
Monday 10 September

5:15PM-5:30PM  MO2 How Errors in the Implementation of Background Mortality Leads to Bias in Models  Bullement A1, Hatswell AJ2, BresMed Health Solutions, Sheffield, UK, 1Delta Hat Limited and University College of London, Nottingham, UK

5:30PM-5:45PM  MO3 Towards a More Accurate Budget Impact Analysis: Population-Level Screening for Hepatitis C Virus in Ontario, Canada  Wong WW1, Hamadeh A1, Haines A2, Feng Z1, Krahn M1, University of Waterloo, Kitchener, ON, Canada, 2Toronto Health Economics and Technology Assessment Collaborative, Toronto, ON, Canada, 1University of Guelph, Guelph, ON, Canada

5:45PM-6:00PM  MO4 Assessing the Appropriateness of Existing Model Adaptation Methods for Low and Middle-Income Countries  Alshreef A1, Macquillan K2, Dawkins B1, Riddin J1, Ward S1, Meads D1, Taylor M1, Dixon S1, Culyer TJ, Hofman K2, Ruiz P1, Chalkidou K1, Lord J1, Edoka I2, 1University of Sheffield, Sheffield, UK, 2University of Witwatersrand, Jo, South Africa, 1University of Leeds, Leeds, UK, 1National Department of Health, Pretoria, South Africa, 2York Health Economics Consortium, University of York, York, UK, 1University of York, York, UK, 1Wits School of Public Health, Johannesburg, South Africa, 1Imperial College London, London, UK, 1University of Southampton, Southampton, UK

6:00PM-7:30PM  EXHIBITORS’ RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III  Hana Ballroom (4th fl)

6:15PM-7:15PM  BREAKOUT SESSION

F1: Understanding the Evolving Healthcare Landscape in Asia Pacific: Real-World Data and HTA  Concord Ballroom A (5th fl)  Asia Consortium Health Technology Producers (Industry) Committee  Moderator: Ramon Lyu, MS, Johnson & Johnson Medical (China) Ltd., Shanghai, China  Speakers: Jianwei Xuan, MD, PhD, Sun Yat-sen University, Guangzhou, China; Sang-Soo Lee, PhD, MBA, Medtronic Korea, Ltd., Seoul, Republic of South Korea; Ruoyan Gai, PhD, National Center for Child Health and Development of Japan, Tokyo, Japan; Bruce C.M. Wang, PhD, Elysia Group, LLC, New York, NY, USA

F2: Health Technology Assessment of Medical Devices in Asia Pacific  Concord Ballroom B (5th fl)  Asia Consortium Health Technology Assessment Agencies, Healthcare Policymakers & Payers Committee  Moderator: Devarshi Bhattacharyya, MSc, MPH, Assistant Director, Kalam Institute of Health Technology (KIHT), Visakhapatnam, India  Speakers: Wudong Guo, PhD, China National Health Development Research Center, National Health Commission, Beijing, China; Richard J Milne, MSc, PhD, University of Auckland, Auckland, New Zealand; Alexander Kostyuk, MD, PhD, Ministry of Health and Social Development, Astana, Kazakhstan; Sukyeong Kim, PhD, RPh, MPH, National Evidence-Based Healthcare Collaborating Agency, Seoul, Republic of South Korea

F3: ISPOR Scientific and Health Policy Groups  Concord Ballroom C (5th fl)  This session will provide an overview of ISPOR’s numerous Scientific and Health Policy Groups that advance health economics and outcomes research and its use in healthcare decisions. These groups consist of Special Interest Groups, Good Practices for Outcomes Research Task Forces, Special Task Forces, and Council Working Groups. Presenters will share the mission and objectives of each group, their current projects, and will explain how ISPOR members can become involved.  Speakers: Clarissa Cooblall, Manager, Scientific and Health Policy Initiatives, ISPOR; Lucinda Orsini, Associate Chief Science Officer, ISPOR

6:30PM-7:30PM  RESEARCH POSTER AUTHOR DISCUSSION HOUR - SESSION III  Hana Ballroom (4th fl)
Tuesday 11 September

7:00AM-5:00PM  
REGISTRATION HELP DESK HOURS  
Hana Foyer (4th fl)

7:15AM-8:15AM  
EDUCATIONAL SYMPOSIUM  
Nishiki Room (4th fl)

Value-Based Decision Making in Developing Countries: Multi-Criteria Decision Analysis (MCDA) for Off-Patent Pharmaceuticals

Developing countries often have challenges managing healthcare budgets without compromising effectiveness and safety of pharmaceuticals. In this session, value-based decision making for off-patent products and adaptation experiences in different developing countries (Indonesia, Vietnam, Kazakhstan, and Kuwait) will be discussed. 
Sponsored by Abbott Established Pharmaceuticals Division (EPD)

8:30AM-10:15AM  
WELCOME & THIRD PLENARY SESSION  
Concord Ballroom (5th fl)

Welcome from ISPOR Asia Consortium Executive Committee Chair
Isao Kamae, MD, DrPH, The University of Tokyo, Tokyo, Japan

ISPOR Distinguished Service Awards
Presented by: Federico Augustovski, MD, MSc, PhD, ISPOR President (2018-2019)
Awardees:
Takashi Fukuda, PhD, ISPOR Asia Pacific 2018 Conference Co-Chair
Shinya Saito, MD, PhD, ISPOR Asia Pacific 2018 Conference Co-Chair
Shunya Ikeda, MD, MS, DrMedSci, ISPOR Asia Pacific 2018 Program Committee Co-Chair
Kun Zhao, MD, PhD, MHSc, ISPOR Asia Pacific 2018 Program Committee Co-Chair
Isao Kamae, MD, DrPH, ISPOR Asia Consortium Executive Committee Chair (2016-2018)
Sukyeong Kim, PhD, ISPOR HTA Roundtable Asia-Pacific Chair (2016-2019)

2018 ISPOR Value in Health Regional Issues (Asia) Excellent Article Award
Presented by: Federico Augustovski, MD, MSc, PhD, ISPOR President (2018-2019) and Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina
Awardee:
Eui-Kyung Lee, PhD, Sungkyunkwan University, Jangan-gu, Suwon, Gyeonggi-do, South Korea

ISPOR Asia Pacific 2020 Announcement
Nancy S. Berg, CEO and Executive Director, ISPOR, Lawrenceville, NJ, USA

Third Plenary Session: Risk-Sharing Agreements: Country Experiences, Challenges, and Lessons Learned
Moderator: Jöerg Mahlich, Head Health Economics and Outcomes Research, Janssen Pharmaceutical, and Formal Director, Health Economics in Janssen Japan KK, Neuss, Germany
Speakers: Elizabeth de Somer, Chief Executive Officer, Medicines Australia, Canberra, Australia; Jang Sae Rak, Deputy Director, Pharmaceutical Listing Division, Pharmaceutical Benefit Department, Health Insurance Review and Assessment Service, Seoul, South Korea; Gergana Zlateva, PhD, Vice President, Global Market Access-Oncology, Global Health & Value, Pfizer Inc., New York, NY, USA

8:30AM-1:45PM  
RESEARCH POSTER PRESENTATIONS - SESSION IV  
Hana Ballroom (4th fl)

10:15AM-10:45AM  
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION IV  
Hana Ballroom (4th fl)

10:45AM-11:45AM  
BREAKOUT SESSION

IP13: MCDA in HTA: Would MCDA Be a Valuable Addition to the Current Japanese HTA System?
Concord Ballroom A (5th fl)
Moderator: Isao Kamae, MD, DrPH, The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan
Panelists: Omer Saka, MD, MSc, Deloitte Belgium, Zaventem, Belgium; Ataru Igarashi, PhD, The University of Tokyo, Tokyo, Japan; Yot Teerawattananon, PhD, HITAP, Nonthaburi, Thailand

IP14: Managed Entry Schemes: Hype vs Reality  
Concord Ballroom B (5th fl)
Moderator: Joshua Byrnes, PhD, Griffith University, Brisbane, Australia
Panelists: Jonathan Karnon, PhD, The University of Adelaide, Adelaide, Australia; Jeonghoon Ahn, PhD, Ewha Womans University, Seoul, Republic of South Korea; Greg Cook, PhD, Bristol Myers Squibb, Mulgrave, Australia
**IP15:** Current Practices and Prospects in Managing Reimbursement in Asia Pacific and Europe: What More Can We Do to Bridge the Experience and Expectation? *Concord Ballroom C (5th fl)*

*Moderator:* Adrián Griffin, MSc, Johnson & Johnson, Buckinghamshire, UK

*Panelists:* Zhao Kun, MD, PhD, MHSc, Division of Health Technology, Beijing, China; Nathorn Chaiyakunapruk, PharmD, PhD, Naresuan University, Phitsanulok, Thailand; Onozaki Kohei, MS, Health and Global Policy Institute, Tokyo, Japan

**W13:** Modeling Disease Progression and Economic Outcomes of Dementia Interventions: Exploring Options for a Complex Health Problem *Nishiki Room (4th fl)*

*Discussion Leaders:* Kim-Huong Nguyen, PhD, University of Queensland, Brisbane, Australia; Brendan Mulhern, MRes, University of Technology Sydney, Sydney, Australia; Tracy Comans, PhD, University of Queensland, Brisbane, Australia; Jasmine Pwu, PhD, MÖHW, Taipei, Taiwan

**W14:** Delayed Access for Patients with Rare Diseases in Asia Pacific: Finding a Solution that Works *Ohgi Room (4th fl)*

*Discussion Leaders:* Annabel Griffiths, PhD, Costello Medical, Cambridge, UK; Ming-Chin Yang, PhD, National Taiwan University, Public Health, Taipei, Taiwan; Shanlian Hu, MD, MSc, Shanghai Health Development Research Center, Shanghai, China; Bertram Haeussler, MD, IGES Institut GmbH, Berlin, Germany

**P10:** Cost-Effectiveness Studies *Grace Room (3rd fl)*

*Moderator:* Ya-Chen Tina Shih, PhD, Professor of Health Economics, & Section Chief, Section of Cancer Economics and Policy, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

**CE1** Cost-Effectiveness of Rivaroxaban and Aspirin Compared to Aspirin Alone in Patients with Stable Cardiovascular Disease: An Australian Perspective

*Ademi Z, Zomer E, Tonkin A, Liew D, Monash University, Melbourne, Australia*

**CE2** Cost-Effectiveness of an Adherence-Enhancing Intervention for Patients With Gout Based on Real-World Data

*Lin LW1, Teng GG2, Lim AV2, Yoong JS1, 1National University of Singapore, Singapore, 2National University Health System, Singapore, Singapore*

**CE3** Cost-Effectiveness of Vedolizumab for the Management of Moderate-to-Severe Ulcerative Colitis in Thailand

*Sruamsiri R, Takeda (Thailand) Ltd, Bangkok, Thailand*

**CE4** Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients With Acute Coronary Syndrome from a Vietnamese Healthcare Payers’ Perspective

*Do VD1, Nguyen TT2, Melistrom C2, Nguyen QT1, Pham MH1, Hoang VS1, Phuong LT1, Nguyen TT1, Luu TC3, 1University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh, Viet Nam, 2University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Viet Nam, 3ASTRAZENECA, Gothenburg, Sweden, 4Hanoi Heart Hospital, Ha Noi, Viet Nam, 5Bach Mai Hospital, Ha Noi, Viet Nam, 6ASTRAZENECA, Ho Chi Minh, Viet Nam*

**LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION IV** *Hana Ballroom (4th fl)*

**EDUCATIONAL SYMPOSIUM** *Nishiki Room (4th fl)*

**Challenges and Opportunities in Value Assessment of Biologic Medicines**

The theme of the symposium will focus on value assessment of innovative biologic medicines, particularly to discuss how the value of innovative biologic medicines should be appropriately assessed from clinical, economic, and humanistic perspective. **Sponsored by Amgen, Inc**

**RESEARCH POSTER AUTHOR DISCUSSION HOUR - SESSION IV** *Hana Ballroom (4th fl)*

**ISPOR NEW PROFESSIONAL EVENT – CAREER ADVICE ACROSS THE GLOBE “PUBLISHING OPPORTUNITIES IN HEOR”** *Ensemble Room (44th fl)*

We invite ISPOR New Professional members, and soon-to-graduate student members, to attend the first ever Career Advice Across the Globe event to be hosted at an ISPOR Asia Pacific conference. Building on the success of the events held at the ISPOR Annual Conferences in the US and Europe, we are pleased to introduce this event for those who are new to the field to receive career advice from seasoned HEOR professionals. This installment will be a roundtable style event that focuses on the topic of “Publishing Opportunities in HEOR.” The session will feature speakers from *Value in Health* and *Value in Health Regional Issues* and attendees will have the opportunity to ask questions about how to maximize their potential of being published.
Tuesday 11 September

1:30PM-2:30PM  EDUCATIONAL SYMPOSIUM  Nishiki Room (4th fl)
The Dynamic Constraints and Future Direction of Healthcare Reform in Japan
This session will focus on the financial constraints driving healthcare reform in Japan, as well as ensuring the effectiveness of health technology assessment (HTA) - process, assessment, and results. We will also discuss the importance of healthcare reform and our view of the future.
Sponsored by Takeda Pharmaceutical Company Limited.

2:45PM-3:45PM  BREAKOUT SESSION

IP16: Does Transparency Help or Hinder Emerging HTA Systems?  Concord Ballroom A (5th fl)
Moderator: Wrik Ghosh, MSc, Costello GK, Singapore, Singapore
Panelists: Thomas Butt, PhD, Peking University, Beijing, China; Fiona Pearce, MPH, Agency for Care Effectiveness, Ministry of Health, Singapore, Singapore; Brenda Pote, Group Market Access Manager, Roche Singapore Pte. Ltd., Singapore, Singapore

IP17: How Collaborative Can Companies Be in Developing Evidence to Support Market Access?
Concord Ballroom B (5th fl)
Moderator: Josie Godfrey, MA, JG Zebra Consulting, London, UK
Panelists: David Pearce, BPharm, MSc, Takeda Pharmaceuticals, Singapore, Singapore; Klair Bayley, BSc, Save Our Sons Duchenne Foundation, Hurlstone Park, Australia; Anthony Hatswell, MSc, Delta Hat, Nottingham, UK

IP18: How to Deal with Model Uncertainty at the Planning Stage of Cost-Effectiveness Analysis: Tips from Global Experiences  Concord Ballroom C (5th fl)
Moderator: Bruno Rossi, BA, Satoru GK, Nishinomiya, Japan
Panelists: George Papadopoulos, GradDipEpi, Lucid Health Consulting Pty. Ltd., NSW, Australia; Joe Caputo, BSc, Vista Health Pte Ltd., Singapore, Singapore; Emiko Yoshida, MSc, Healthcare to All, Tokyo, Japan

Discussion Leaders: Jiu-Hong Wu, PhD, PharmD, The 306th Hospital of PLA, Beijing, China; Feng Xie, BSc MSc PhD, McMaster University, Hamilton, ON, Canada; Fei-Li Zhao, BPharm, MS, PhD, Beijing Health Economics Association, Beijing, China

W16: The Application of Indication Based Pricing to Regenerative Medicine Therapies: An Interactive Workshop  Ohgi Room (4th fl)
Discussion Leaders: Diana Brixxner, PhD, RPh, FAMCP, University of Utah, Salt Lake City, UT, USA; Masayuki Yamato, PhD, Tokyo Women’s Medical University, Tokyo, Japan; Joe Caputo, BSc, Vista Health Pte Ltd., Singapore, Singapore; Emiko Yoshida, MSc, Healthcare to All, Tokyo, Japan

P11: Utility and Patient Preference Studies  Grace Room (3rd fl)
Moderator: Jing Wu, PhD, Tianjin University, Tianjin, China

2:45PM-3:00PM  PP1  Consumer Preferences for Nutraceuticals: Pilot-Testing for Discrete Choice Experiment
Teoh SL1, Ngorsuraches S2, Chaiyakunapruk N3, 1Monash University Malaysia, Selangor, Malaysia, 2South Dakota State University, Brookings, SD, USA, 3Monash University, Petaling Jaya, Malaysia

3:00PM-3:15PM  PP2  Are Time Trade-Off Values of Worse-Than-Death Health States Valid?
Gandhi M1, Rand K2, Luo N3, 1Singapore Clinical Research Institute, Singapore, Singapore, Singapore, 2University of Oslo, Oslo, Norway, 3National University of Singapore, Singapore

3:15PM-3:30PM  PP3  Patient Preference Study on Treatments of Non Small Cell Lung Cancer in Western China
Zhou N1, Liu F1, Hu M1, Wang J1, Yang N3, Chen Y3, Sun H2, 1Sichuan University, Chengdu, China, 2Fudan University, Shanghai, China

3:30PM-3:45PM  PP4  A Novel, Simple and Accurate Method to Map Quality-of-Life Scores to Utility Values
Cheung YB1, Wee HL2, Khoo EY3, Chong BK1, Yeo KK1, Lee CF2, Ng R3, Luo N1, 1Duke-NUS Medical School, Singapore, Singapore, 2National University of Singapore, Singapore, Singapore, 3National University Hospital System, Singapore, Singapore, Singapore, 4National Heart Center, Singapore, Singapore, Singapore, 5University of Hong Kong, Hong Kong, China, 6National Cancer Center, Singapore, Singapore

4:00PM-5:00PM  BREAKOUT SESSION

IP19: Overdiagnosasis and Its Excess Cost for Cancer Screening  Concord Ballroom A (5th fl)
Moderator: Tony Hsiu-Hsi Chen, PhD, National Taiwan University Hospital, Taipei, Taiwan
Panelists: Amy Ming-Fang Yen, PhD, Taipei Medical University, Taipei, Taiwan; Sherry Yueh-Hsia Chiu, PhD, Chang Gung University, Taoyuan, Taiwan; Chisato Hamashima, MD, Teikyo University, Tokyo, Japan
Tuesday 11 September

**IP20:** Discrete Choice Experiments as a Measure of Social Value and Preferences: Application to Policy Making in Asia Pacific  
*Concord Ballroom B (5th fl)*

**Moderator:** Brendan Mulhern, MRes. University of Technology Sydney, Sydney, Australia  
**Panelists:** Stephen Goodall, BSc, MSC, PhD, University of Technology Sydney, Sydney, Australia; Timothy Bolt, PhD, Saitama University, Saitama, Japan; Ruoyan Gai, PhD, National Center for Child Health and Development of Japan, Tokyo, Japan

**IP21:** Does Overseas Experience of Managed Entry Agreements Inform the New Japanese Pricing Scheme for Medical Devices?  
*Concord Ballroom C (5th fl)*

**Moderator:** Michael F. Drummond, MCom, DPhil. University of York, York, UK  
**Panelists:** Makoto Tamura, PhD, International University of Health and Welfare, Ohtawara City, Japan; Kosuke Kato, PhD. American Medical Devices and Diagnostics Manufacturers' Association, Nakano-ku, Japan

**W17:** How E-Connected Medicine Will Change the Value of Pharmaceuticals  
*Nishiki Room (4th fl)*

**Discussion Leaders:** Taishiro Kishimoto, MD, PhD, Keio University, School of Medicine, Tokyo, Japan; Ataru Igarashi, PhD. University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan; Yasuko Aitoku, BS, Bayer Yakuhin Ltd., Osaka, Japan; Mondher Touni, MD, PhD, MSc, Aix-Marseille University, Marseille, France

**W18:** Value of Information Analysis: Principles, Applications, and Good Practice Recommendations  
*Ohgi Room (4th fl)*

**Discussion Leaders:** Haitham Tuffaha, BPharm, MBA, MSC, PhD. Griffith University, Brisbane, Australia; Lotte Steuten, PhD, MSc. Fred Hutchinson Cancer Research Center, Seattle, WA, USA

**P12:** Drug Use and Disease Management Studies  
*Grace Room (3rd fl)*

**Moderator:** Eui-Kyung Lee, PhD, RPh. SungKyunkwan University, Seoul, South Korea

4:00PM-4:15PM  
**DU1** Early Initiation of Long-Acting Injectable Antipsychotic Treatment Is Associated with Lower Healthcare Resource Use and Costs in Patients with Schizophrenia  
Munday JS	extsuperscript{1}, Broder MS	extsuperscript{1}, Chang E	extsuperscript{1}, Hartry A	extsuperscript{2}, Yan T	extsuperscript{1}, Greene M	extsuperscript{1}  
	extsuperscript{1}Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA,  
	extsuperscript{2}Lundbeck, Deerfield, IL, USA,  
	extsuperscript{3}Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA

4:15PM-4:30PM  
**DU2** Star Analysis of Value for Money for Use of Oral Anticoagulants  
Orlowski A	extsuperscript{1}, Ashton R	extsuperscript{1}, Glover R	extsuperscript{1},  
	extsuperscript{1}Imperial College Health Partners, London, UK,  
	extsuperscript{2}North England Commissioning Unit, Durham, UK

4:30PM-4:45PM  
**DU3** Why Aren't You Prescribing My Drug? Physician Concerns of Biologics for Rheumatoid Arthritis in China  
Furnback W	extsuperscript{1}, Wang BC	extsuperscript{2},  
	extsuperscript{1}Evipoint, LLC, Point Pleasant, NJ, USA,  
	extsuperscript{2}Elysia Group, LLC, New York, NY, USA

4:45PM-5:00PM  
**DU4** The Impact of Glycemic Control on Cognition in People with Type 2 Diabetes  
Hammad MA	extsuperscript{1}, Sulaiman SA	extsuperscript{1}, Aziz NA	extsuperscript{2}, Zaitoun M	extsuperscript{1}, Mohamed Noor DA	extsuperscript{1},  
	extsuperscript{1}Universiti Sains Malaysia, Penang, Malaysia,  
	extsuperscript{2}Penang General Hospital, Penang, Malaysia,  
	extsuperscript{3}Armed Forces Hospitals Southern Region, Khamis Mushait, Saudi Arabia

---

**ISPOR Conference Evaluation**

We're listening.

Please complete a simple online evaluation after the conference to help us plan for future conferences. It's simple, answer 10 multiple-choice questions by Friday, September 28, 2018 using the ISPOR mobile app or on the ISPOR website at www.ispor.org.

Be a voice and help us plan for 2020.

**ISPOR Session Evaluation**

Have thoughts about a particular session? We're interested.

- Evaluate presentations through the ISPOR Mobile App
- Provide real-time responses immediately following the presentation
- 2-question evaluation for each presentation that can be accessed through the description portion of the presentation on the app.
Invitational Group Meetings

The following is a list of the by invitation only ISPOR group meetings during ISPOR Asia Pacific 2018. ISPOR members worldwide actively participate in ISPOR working groups to advance global health outcomes research and the use of this research in healthcare decisions. These ISPOR groups provide an opportunity for members to contribute to translating outcomes research into healthcare decisions.

Please note: invitees will receive an email reminder and notification of any changes to this ISPOR group meeting schedule

<table>
<thead>
<tr>
<th>SATURDAY, SEPTEMBER 8, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00AM-3:30PM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SUNDAY, SEPTEMBER 9, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00AM-12:30PM</td>
</tr>
<tr>
<td>8:30AM-12:30PM</td>
</tr>
<tr>
<td>3:30PM-7:30PM</td>
</tr>
<tr>
<td>3:45PM-4:45PM</td>
</tr>
<tr>
<td>5:00PM-6:00PM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MONDAY, SEPTEMBER 10, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30AM-11:30AM</td>
</tr>
<tr>
<td>10:30AM-11:30AM</td>
</tr>
<tr>
<td>1:00PM-5:00PM</td>
</tr>
<tr>
<td>2:15PM-3:15 PM</td>
</tr>
<tr>
<td>5:00PM-6:00PM</td>
</tr>
<tr>
<td>6:10PM-10:00PM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TUESDAY, SEPTEMBER 11, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45AM-11:45AM</td>
</tr>
</tbody>
</table>
Through its local member groups, conferences, and region-specific publications, ISPOR provides a wide array of resources and tools to help all healthcare stakeholders in the region apply the best scientific methodologies to health economics and outcomes research.

Membership + Conferences
• 12% of ISPOR members are located in Asia Pacific countries
• 400% growth in attendance at ISPOR’s Asia Pacific conferences since 2003

Asia Consortium and Regional Chapters
• 32 Regional Chapters in Asia Pacific
• 7 working committees
• In the past 14 years, the Asia Consortium has grown from 13 founding members to 1000 members, making a combined total of 3600 consortia and chapter members in the Asia Pacific region

Publications
• *Value in Health Regional Issues* publishes scientific, peer-reviewed research specific to the Asia Pacific region
• *News Across Asia* features health policy, regional initiatives, and member-reported news in a concise quarterly newsletter

Get Involved
• Attend Asia Pacific and other ISPOR conferences throughout the year
• Join Asia Consortium working groups
• Learn about Regional Chapters in Asia Pacific
Poster - Exhibit Program

Research Poster Presentations Overview

Exhibit Program Overview

Exhibitor Listing

Exhibit/Poster Hall Floor Plan
Research Poster Presentations Overview

Over 700 poster presentations will be on display during the conference in the Poster & Exhibit Hall Hana Ballroom ABC (4th fl).

• Presenters are required to be with their posters during the Poster Author Discussion Hour.
• The poster hall is in rows (A-P) and each poster board is numbered accordingly (e.g. A1-P3)
• Each poster presentation is assigned a numbered board location, which is shown next to the poster presentation title. Please note this is different from the poster code (e.g. PHP1, PCV35), which was assigned to each poster presentation upon acceptance.
• Poster presentation titles and authors, as well as the numbered board location, are available on the myISPORTokyo.zerista.com web platform and mobile app. This information is also available as a PDF on the ISPOR website.
• Poster board numbering is available on the floor plan on page 34 and row locations (by topic) are available in the table below.

Poster Presentations Display Hours

<table>
<thead>
<tr>
<th>POSTER PRESENTATION SESSIONS</th>
<th>POSTER LOCATION</th>
<th>PRESENTER SET UP TIME</th>
<th>POSTER DISPLAY HOURS</th>
<th>AUTHOR DISCUSSION HOUR</th>
<th>PRESENTER DISMANTLE TIME*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SESSION I: SUNDAY, 9 SEPTEMBER</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMD: MEDICAL DEVICE/DIAGNOSTICS</td>
<td>Rows A-C</td>
<td>12:15PM - 12:30PM</td>
<td>12:30PM - 7:30PM</td>
<td>6:30PM - 7:30PM</td>
<td>7:30PM</td>
</tr>
<tr>
<td>PCN: CANCER</td>
<td>Rows C-K</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMH: MENTAL HEALTH</td>
<td>Rows K-M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSS: SENSORY SYSTEMS DISORDERS</td>
<td>Rows N-P</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SESSION II: MONDAY, 10 SEPTEMBER</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHP: HEALTHCARE USE &amp; POLICY STUDIES</td>
<td>Rows A-H</td>
<td>8:15AM - 8:30AM</td>
<td>8:30AM - 1:30PM</td>
<td>12:30PM - 1:30PM</td>
<td>1:30PM</td>
</tr>
<tr>
<td>PGI: GASTROINTESTINAL DISORDERS</td>
<td>Rows H-I</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PIH: INDIVIDUAL’S HEALTH</td>
<td>Rows I-J</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSY: SYSTEMIC DISORDERS/CONDITIONS</td>
<td>Rows K-M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PUK: URINARY/KIDNEY DISORDERS</td>
<td>Rows M-O</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SESSION III: MONDAY, 10 SEPTEMBER</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PIN: INFECTION</td>
<td>Rows A-D</td>
<td>2:15PM - 2:30PM</td>
<td>2:30PM - 7:30PM</td>
<td>6:30PM - 7:30PM</td>
<td>7:30PM</td>
</tr>
<tr>
<td>PMS: MUSCULAR-SKELETAL DISORDERS</td>
<td>Rows D-F</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMU: MULTIPLE DISEASES</td>
<td>Rows F-K</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PND: NEUROLOGICAL DISORDERS</td>
<td>Rows K-L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRS: RESPIRATORY-RELATED DISORDERS</td>
<td>Rows L-N</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SESSION IV: TUESDAY, 11 SEPTEMBER</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRM: RESEARCH ON METHODS</td>
<td>Rows A-E</td>
<td>8:15AM - 8:30AM</td>
<td>8:30AM - 1:45PM</td>
<td>12:45PM - 1:45PM</td>
<td>1:45PM</td>
</tr>
<tr>
<td>PCV: CARDIOVASCULAR DISORDERS</td>
<td>Rows E-I</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDB: DIABETES/ENDOCRINE DISORDERS</td>
<td>Rows J-M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCP: CONCEPTUAL PAPERS</td>
<td>Rows M-N</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Posters that are not removed at the scheduled dismantle times will be discarded.
Exhibit Program Overview

**Exhibit Viewing** *Hana Ballroom (4th Floor)*

- **Sunday, 9 September**  12:00PM-7:30PM
- **Monday, 10 September**  8:30AM-7:30PM
- **Tuesday, 11 September**  8:30AM-1:45PM

### Exhibitor Directory

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Exhibit Table Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amaris Consulting UK Ltd</td>
<td>#23 (Hana Ballroom Lobby)</td>
</tr>
<tr>
<td>BaseCase</td>
<td>#10</td>
</tr>
<tr>
<td>Clinical Study Support, Inc.</td>
<td>#24 (Hana Ballroom Lobby)</td>
</tr>
<tr>
<td>Costello Medical Singapore Pte Ltd</td>
<td>#12</td>
</tr>
<tr>
<td>Creativ-Ceutical</td>
<td>#19</td>
</tr>
<tr>
<td>CRECON MEDICAL ASSESSMENT INC.</td>
<td>#4 &amp; #5</td>
</tr>
<tr>
<td>GfK Health</td>
<td>#16</td>
</tr>
<tr>
<td>ICON</td>
<td>#9</td>
</tr>
<tr>
<td>IQVIA</td>
<td>#2 &amp; #3</td>
</tr>
<tr>
<td>JMDC Inc.</td>
<td>#18</td>
</tr>
<tr>
<td>Kantar Health</td>
<td>#6 &amp; #7</td>
</tr>
<tr>
<td>MAESTRO Database</td>
<td>#13</td>
</tr>
<tr>
<td>Medical Data Vision Co. Ltd.</td>
<td>#15</td>
</tr>
<tr>
<td>Normin Health</td>
<td>#17</td>
</tr>
<tr>
<td>Pharmerit International</td>
<td>#1</td>
</tr>
<tr>
<td>Prioritis Ltd</td>
<td>#11</td>
</tr>
<tr>
<td>RWS Life Sciences</td>
<td>#14</td>
</tr>
<tr>
<td>Syneos Health</td>
<td>#8</td>
</tr>
</tbody>
</table>

*Subject to change*
Exhibit/Poster Hall Floor Plan

Poster Presentations

Session I  Sunday, 9 September  12:00PM–7:30PM
Session II  Monday, 10 September  8:30AM-1:30PM
Session III  Monday, 10 September  2:30PM-7:30PM
Session IV  Tuesday, 11 September  8:30AM–1:45PM
Before it became a medicine,
It was 3,000 researched compounds.
87 different protein structures.
500,000 lab tests.
1,600 scientists.
80-hour workweeks.
34 years of breakthroughs and setbacks.
36 clinical trials.
8,500 patient volunteers.
And more problems to solve than we could count.
Before it became a medicine,
It was an idea in the mind of a Pfizer scientist.
Now it's a medicine
That saves lives every day.

Takeda Oncology
WE ASPIRE TO CURE CANCER.

At Takeda Oncology, we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.

Learn more about our global commitment to oncology. Visit us online at takedaoncology.com.

Takeda Oncology is the oncology business unit brand of Takeda Pharmaceutical Company Limited. ©2017 Millennium Pharmaceuticals, Inc. All rights reserved.

HEOR Resources

Good Practices for Outcomes Research
Pharmacoeconomic Guidelines Around the World
Global Healthcare Systems Road Maps
Scientific Presentations Database
International Digest of Databases
Assessing the Evidence for Decision Makers
Outcomes Research Guidelines Index
Health Technology Assessment Central

www.ispor.org
Key Information

WI-FI AND MOBILE APP ACCESS
For the convenience of conference attendees, Wi-Fi is available in the hotel.
NETWORK: ISPOR / WI-FI PASSWORD: TOKYO2018
Wi-Fi is only intended for checking email and using the conference mobile app, not for downloading files. Connection speeds will vary depending on the volume of users.
Download the mobile app on your smartphone or tablet

Can’t download the app? Use your web browser: https://myISPORtokyoinstall.com/
Use the same details as used for the myISPORtokyo web pages. Your ISPOR mobile app account email address is the same email address used for your conference registration.
Need help? Select “Need help logging in?” on the login screen.
Mobile App Sponsored by HealthCore, Inc.

REGISTRATION DISCLAIMER
For security purposes all individuals must be registered and wear the official ISPOR Conference Name Badge to gain access to the conference, the sessions, the exhibit poster hall, and any ISPOR activity. Onsite staff and security will monitor for name badges and will deny access if individual does not have an official ISPOR Conference Name Badge. Individuals not wearing a name badge will be directed to registration. Please note if you lose your name badge and need to have it re-printed you cannot print that at the self-serve station, you will need to visit the registration help desk.
Sharing of conference name badges is prohibited.
Because of the professional nature of the program and safety and liability concerns, guests and individuals under age 18 are not permitted access or to register for the conference. This includes access to the conference in general, to scientific presentations, and to the exhibit and poster hall.

LANGUAGE INFORMATION
All sessions at ISPOR Asia Pacific 2018 are presented in English. ISPOR regrets that due to the disruption to other delegates, whisper translation (chuchotage) is not permitted in any session, including short courses. To discuss options to meet educational needs in multiple languages, please contact meetingsinfo@ispor.org.

PRESENTATION SLIDES/POSTERS
Plenary session, issue panel, workshop, ISPOR forum, and symposia slides will be available via the conference app and at the ISPOR Asia Pacific 2018 Released Presentations page at www.ispor.org during/after the conference, subject to speaker approval. The Released Presentations page will feature many of the conference's slide presentations as PDFs. In 2016, more than 80% of the presentations were available to the public during/after the conference. The Released Presentations page is accessible via the conference mobile app and at https://www.ispor.org/guestindex2018tokyo
Podium and poster presentation abstracts and released slides or poster PDFs are available at the ISPOR Scientific Presentations Database (a searchable database of over 45,000 research papers presented at ISPOR conferences) at https://tools.ispor.org/RESEARCH-STUDY-DIGEST/research_index.asp

SPEAKER INFORMATION
Upload the final version of your slide presentation in the Speaker Ready Room on the same day of your session.
All speakers are encouraged to use the Speaker Ready Room to preview their slide presentation and/or upload an updated version. Presentations submitted to ISPOR Speaker's Corner by the specified advance deadline and all presentations uploaded/updated in the Speaker Ready Room 30 minutes prior to the session will be pre-loaded to the computer in the session room. All speakers are expected to arrive at their presentation room 15 minutes prior to the session start time. ISPOR staff will be available in the session room to assist the presenter.
The speaker ready room is located in Kaede (4th fl) by the following hours:
- Sunday, 9 September: 12:00PM-6:00PM
- Monday, 10 September: 8:00AM-6:00PM
- Tuesday, 11 September: 8:00AM-4:00PM

ISPOR RESEARCH PRESENTATION AWARDS
Awards are given for the best research presentations for podium presentations (up to 6) and for poster presentations (up to 6).
All research podium presentations are considered for an award. The top 10% of research poster presentations, based on abstract review score, are considered for a poster presentation award. These are identified with a rosette and will be judged during the conference.
Award recipients will be notified by mail and recognized on the ISPOR website at the conclusion of the conference.

SOCIAL MEDIA
Communicating by way of social media is encouraged if it falls within embargo and communications rules.

Be part of the live discussion!
• Tweet your comments to @ISPORorg during the conference using #ISPORTokyo
• Access expert insights and share your views on conference sessions at the ISPOR LinkedIn Discussion Group: http://bit.ly/ISPOR-Ln
• Network with your peers on the ISPOR Facebook page: http://bit.ly/ISPOR-Fb

RECORDING & PRESS INFORMATION
ISPOR supports the promotion of research presented at ISPOR conferences, while safeguarding sensitive information, data, and research findings that are not yet available to the public. Due to the sensitive nature of data—particularly preliminary, unpublished research findings—all filming and recording of scientific sessions and the poster hall are prohibited during the conference, without the express written consent of ISPOR.
Portions of ISPOR Asia Pacific 2018 may be recorded by ISPOR – the professional society for health economics and outcomes research. By participating in the discussions, conference registrants agree that ISPOR may electronically copy, videotape, or audiotape their attendance at and involvement in any program. Registration and attendance at ISPOR Asia Pacific 2018 constitutes an agreement by the registrant to ISPOR’s use and distribution (both now and in the future) of their image or voice in photographs, videotapes, electronic reproductions, and audiotape of such events and activities. ISPOR will strictly enforce its rights as the exclusive licensee of all publication and reproduction rights to each presentation, and no presentation, in whole or in part, may be reproduced without approval from ISPOR.
Conference attendees must gain approval from a speaker or poster presenter prior to quoting or publishing that individuals’ scientific results. Members of the press must identify themselves as such before questioning speakers and conference attendees if using the information in a professional capacity.
More detailed information on ISPOR’s Press Pass, Legal, and Embargo Policies are available on ISPOR’s News & Press page at the ISPOR website (www.ispor.org).
For further questions on these policies, please contact: press@ispor.org

SAFETY AND RESPONSIBILITY POLICY
ISPOR is committed to providing a safe, productive, and welcoming environment for all participants and staff. All participants, including, but not limited to, attendees, speakers, volunteers, exhibitors, ISPOR staff, service providers, and others, are expected to abide by the Safety and Responsibility Policy as noted on our website under Attendee Information > Key Information.

CONFERENCE PROGRAM DISCLAIMER
Please be advised that while the conference program is designed to provide accurate information regarding the subject matter covered, the views, opinions, and recommendations expressed are those of the authors and speakers, not of ISPOR – the professional society for health economics and outcomes research, and thus ISPOR does not guarantee the accuracy of the information disseminated. If professional advice is desired, please consult a competent professional.

ANTITRUST COMPLIANCE
It is the underscoring policy of ISPOR to comply strictly with the letter and spirit of all local and U.S. Federal, and applicable international trade regulations and antitrust laws. Any activities of ISPOR or ISPOR-related actions of its officers, Executive Committee Members, or members that violate these regulations and laws are detrimental to the interests of ISPOR and are unequivocally contrary to ISPOR policy.

FINANCIAL DISCLOSURE INFORMATION
Research podium and poster presentation financial disclosure information will be available online at: https://www.ispor.org/funding-statement in Value in Health (Volume 21, Suppl 2) in September 2018. Faculty and staff involved in the planning or presentation of this conference are required to disclose all real or apparent commercial financial affiliations related to conference content. This information is available on request at the ISPOR Registration desk.

QUESTIONS & INFORMATION
Please ask ISPOR staff members for any additional information about the conference or about ISPOR. ISPOR staff can be identified by their ISPOR name badge.
1. **Drug Pricing and Spending**
   Conversations on how to manage drug prices are intensifying, with a particular focus on ensuring that drug prices reflect the value of treatment.

2. **Innovative and Curative Therapies**
   As drug discovery and healthcare move toward more personalized medical treatment, novel therapies will continue to be developed.

3. **Accelerated Drug Approvals**
   Regulatory efforts continue to speed the approval of new drugs that conquer unmet medical needs and get much-needed therapies to patients, yet in making them widely available, reimbursement is equally important.

4. **Universal Health Coverage**
   Globally, a growing commitment to universal health coverage is elevating the role of HEOR.

5. **Aging Population**
   The world is getting older. By 2050, the number of people over 65 is expected to reach 1.5 billion. It is crucial that healthcare spending be managed to deliver outcomes most desired by our aging population.

6. **mHealth**
   There is rising optimism about the potential of mHealth (mobile health) to cost-effectively improve patient care.

7. **Diagnostics**
   With the launch of more advanced—and even more costly—therapies, the need for jointly developed diagnostics to ensure the right patients are benefiting from them has grown even more essential.

8. **Biosimilars**
   Biosimilars have the potential to give patients a wide variety of treatment options—and to provide savings to the entire healthcare system.

9. **Preventive Medicine**
   Health economic evaluation is particularly important for preventive medicine that improves healthcare worldwide.

10. **Disruptive Innovators**
    In the past decade, scientific innovations in cell and gene research have been creating new therapies that pose novel challenges to those involved in health technology assessment and healthcare decision making.

Download the full report at www.ispor.org
Conference Rooms Floor Plans

5Fご案内

4Fご案内

3Fご案内
ISPOR—The Professional Society for Health Economics and Outcomes Research

ISPOR 2018 Conferences

**ISPOR Dubai 2018**

19-20 September 2018 / Dubai, United Arab Emirates

*Healthcare Decision Making in the Middle East and North Africa: Role of Health Economics, Outcomes Research, and Health Technology Assessment*

Register today.

**ISPOR Summit**

October 19, 2018 / Washington, DC, USA

*New Approaches to Value Assessment – Towards More Informed Pricing in Healthcare*

Hotel discounts through September 27, based on availability.

**ISPOR Europe 2018**

10-14 November 2018 / Barcelona, Spain

*New Perspectives for Improving 21st Century Health Systems*

Register by 25 September for savings.

---

**ISPOR 2019 CONFERENCES**

**ISPOR 2019**

May 18-22, 2019
New Orleans, LA, USA

Abstract Submission Opens: October 1, 2018

**ISPOR Latin America 2019**

12-14 September 2019
Bogotá, Colombia

Abstract Submission Opens: 1 December 2018

**ISPOR Warsaw 2019**

March 2019
Warsaw, Poland

Details to come

**ISPOR Europe 2019**

2-6 November 2019
Copenhagen, Denmark

Abstract Submission Opens: 1 March 2019

FOR MORE INFORMATION AND TO REGISTER: [www.ispor.org](http://www.ispor.org)